Tested.Agent.s.,Combined.Agent.s.,Control.Arm,Treatment.Setting,Tumour.Type,Tumour.Sub.type,Tumour.Sub.group,Tumour.Stage,Score,Ref.,Score.card,V1,V2,V3,Control Arm,DFS Control,DFS Gain,DFS HR,Final curative score,Form(s),Primary Outcome(s),Treatment Setting,Trial Name,Tumour stage,Tumour Sub-Group,Tumour Sub-type,Tumour Type,Combined Agent(s),pCR Gain,PFS HR,Final non-curative Score,OS Control,OS Gain,OS HR,PFS Control,PFS Gain,Preliminary non-curative score,QoL adjustment,QoL Comment,Last update,Toxicity adjustment,Toxicity Comment,Long-term plateau in the survival curve,Evaluated Outcome,V4,Comment,Long-term plateau in the PFS curve,QoL or Toxicity non-inferiority or superiority in PFS/OS,Release date,ORR,Issue date,DoR,RR Gain,Improvement in some symptoms BUT without evidence of improved overall QoL,RFS Control,RFS Gain,RFS HR,OS advantage continues to be observed
Trastuzumab,-,Chemotherapy,Adjuvant or neo-adjuvant HER2 positive tumours,Breast Cancer,Breast Cancer,HER2+,Early,A,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa052306?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA,Chemotherapy,2 years DFS 77.4%,"8,40 %",0.54 (0.43-0.67),A,Form 1,DFS,Adjuvant or neo-adjuvant HER2 positive tumours,HERA,            Early    ,HER2+,Breast Cancer,Breast Cancer,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Pertuzumab,Trastuzumab + docetaxel,Trastuzumab + docetaxel                                             (Randomised phase II study),Neo-adjuvant HER2 overexpressed invasive ductal breast,Breast Cancer,Breast Cancer,HER2+,Early,C,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70336-9/fulltext,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)00163-7/fulltext,NA,Trastuzumab + docetaxel                                             (Randomised phase II study),NA,NA,NA,C,Form 1,pCR ,Neo-adjuvant HER2 overexpressed invasive ductal breast,Neo Sphere,            Early    ,HER2+,Breast Cancer,Breast Cancer,Trastuzumab + docetaxel,46% vs 29%,NS,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
T-DM1,-,Lapatinib + capecitabine,2nd line metastatic after trastuzumab failure (extensive crossover),Breast Cancer,Breast Cancer,HER2+,Metastatic,4,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1209124?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.28465,NA,Lapatinib + capecitabine,NA,NA,NA,NA,Form 2a,PFS and OS,2nd line metastatic after trastuzumab failure (extensive crossover),EMILIA,            Metastatic    ,HER2+,Breast Cancer,Breast Cancer,NA,NA,0.65 (0.55-0.77),4,25.1 months,5.8 months,0.68 (0.55-0.85),6.4 months,3.2 months,3,1+,Delayed deterioration,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Pertuzumab,Trastuzumab + docetaxel,Trastuzumab + docetaxel + placebo,1st line metastatic,Breast Cancer,Breast Cancer,HER2+,Metastatic,4,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1413513?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,https://www.nejm.org/doi/10.1056/NEJMoa1113216?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,https://academic.oup.com/annonc/article/24/10/2630/176992,Trastuzumab + docetaxel + placebo ,NA,NA,NA,NA,Form 2a,PFS,1st line metastatic,CLEOPATRA,            Metastatic    ,HER2+,Breast Cancer,Breast Cancer,Trastuzumab + docetaxel,NA,0.62 (0.52-0.75),4,40.8 months,15.7 months,0.68 (0.56-0.84),12.4 months,6.3 months,4,NA,No improvement,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Trastuzumab,Lapatinib,Lapatinib,3rd line metastatic,Breast Cancer,Breast Cancer,HER2+,Metastatic,4,NA,NA,http://ascopubs.org/doi/abs/10.1200/JCO.2011.35.6725?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,NA,NA,Lapatinib ,NA,NA,NA,NA,Form 2a,PFS,3rd line metastatic,EGF104900,            Metastatic    ,HER2+,Breast Cancer,Breast Cancer,Lapatinib,NA,0.73 (0.57-0.93),4,9.5 months,4.5 months,0.74 (0.57-0.97),2 months,1 month,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Palbociclib,Fulvestrant,Fulvestrant + placebo,2nd line metastatic HR+ HER2-,Breast Cancer,Breast Cancer,HR+ HER2-,Metastatic,4,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00613-0/fulltext,https://www.nejm.org/doi/full/10.1056/NEJMoa1810527?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,https://www.annalsofoncology.org/article/S0923-7534(19)35655-8/fulltext,Fulvestrant + placebo,NA,NA,NA,NA,Form 2b,PFS,2nd line metastatic HR+ HER2- ,PALOMA-3,            Metastatic    ,HR+ HER2-,Breast Cancer,Breast Cancer,Fulvestrant,NA,0.46 (0.36-0.59),4,28.0 months,6.9 months,Not significant,4.6 months,4.9 months,3,1+,Delayed deterioration,11.05.2020,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Palbociclib,Letrozole,Letrozole + placebo,1st line metastatic HR+ HER2-,Breast Cancer,Breast Cancer,HR+ HER2-,Metastatic,3,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1607303?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA,Letrozole + placebo,NA,NA,NA,NA,Form 2b,PFS,1st line metastatic HR+ HER2- ,PALOMA-2,            Metastatic    ,HR+ HER2-,Breast Cancer,Breast Cancer,Letrozole,NA,0.58 (0.46-0.72),3,NA,NA,NA,14.5 months,10.3 months,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Palbociclib,Letrozole,Letrozole (Randomised phase II study),1st line metastatic HR+ HER2-,Breast Cancer,Breast Cancer,HR+ HER2-,Metastatic,3,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71159-3/fulltext,NA,NA,Letrozole (Randomised phase II study)  ,NA,NA,NA,NA,Form 2b,PFS,1st line metastatic HR+ HER2- ,PALOMA-1/TRIO-18,            Metastatic    ,HR+ HER2-,Breast Cancer,Breast Cancer,Letrozole,NA,0.49 (0.32-0.75),3,33.3 months,4.2 months,NS,10.2 months,10 months,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Ribociclib,Letrozole,Letrozole + placebo,1st line metastatic post-menopause HR+ HER2-,Breast Cancer,Breast Cancer,HR+ HER2-,Metastatic,3,NA,NA,https://academic.oup.com/annonc/article/29/7/1541/4989216,NA,NA,Letrozole + placebo,NA,NA,NA,NA,Form 2b,PFS,1st line metastatic post-menopause HR+ HER2-,MONALEESA-2,            Metastatic    ,HR+ HER2-,Breast Cancer,Breast Cancer,Letrozole,NA,0.57 (0.46-0.70),3,NA,NA,Not mature data,16 months,9.3 months,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Lapatinib,Capecitabine,Capecitabine,2nd line metastatic after trastuzumab failure,Breast Cancer,Breast Cancer,HER2+,Metastatic,3,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa064320?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA,Capecitabine,NA,NA,NA,NA,Form 2b,TTP,2nd line metastatic after trastuzumab failure,NA,            Metastatic    ,HER2+,Breast Cancer,Breast Cancer,Capecitabine,NA,0.49 (0.34-0.71),3,NA,NA,NS,4.4 months,4 months,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Bevacizumab,Paclitaxel,Paclitaxel,1st line metastatic (no crossover),Breast Cancer,Breast Cancer,-,Metastatic,2,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa072113?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA,Paclitaxel ,NA,NA,NA,NA,Form 2b,PFS,1st line metastatic (no crossover),NA,            Metastatic    ,NA,Breast Cancer,Breast Cancer,Paclitaxel,NA,0.60 (0.51-0.70),2,NA,NA,NS,5.9 months,5.9 months,3,-1,No improvement,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Everolimus,Exemestane,Exemestane + placebo,Metastatic after failure of aromatose inhibitor (with PFS> 6 months) (no crossover),Breast Cancer,Breast Cancer,HR+,Metastatic,2,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1109653?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA,Exemestane + placebo,NA,NA,NA,NA,Form 2b,PFS,Metastatic after failure of aromatose inhibitor (with PFS> 6 months) (no crossover),BOLERO-2,            Metastatic    ,HR+,Breast Cancer,Breast Cancer,Exemestane,NA,0.36 (0.27-0.47),2,NA,NA,NS,4.1 months,6.5 months,2,NA,No improvement,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Eribulin,-,Treatment of physician's choice,3rd line metastatic after anthracycline and taxane,Breast Cancer,Breast Cancer,-,Metastatic,2,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)60070-6/fulltext,NA,NA,Treatment of physician's choice,NA,NA,NA,NA,Form 2a,OS,3rd line metastatic after anthracycline and taxane,EMBRACE,            Metastatic    ,NA,Breast Cancer,Breast Cancer,NA,NA,NA,2,10.6 months,2.5 months,0.81 (0.66-0.99),NA,NA,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Eribulin,-,Treatment of physician's choice,3rd line metastatic after anthracycline and taxane in HER2 negative patients,Breast Cancer,Breast Cancer,HER2-,Metastatic,1,NA,NA,https://academic.oup.com/annonc/article/27/8/1525/1741475,NA,NA,Treatment of physician's choice,NA,NA,NA,NA,Form 2a,OS,3rd line metastatic after anthracycline and taxane in HER2 negative patients,Pooled analysis,            Metastatic    ,HER2-,Breast Cancer,Breast Cancer,NA,NA,NA,1,12 months,3.1 months,0.84 (0.74-0.96),NA,NA,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Panitumumab,FOLFOX4,FOLFOX4,"1st line metastatic colorectal cancer (post hoc KRAS, NRAS BRAF WT)",Gastrointestinal Cancers,Colon and Rectal Cancer,-,Metastatic,4,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1305275?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA,FOLFOX4,NA,NA,NA,NA,Form 2a,PFS,"1st line metastatic colorectal cancer (post hoc KRAS, NRAS BRAF WT)",PRIME,            Metastatic    ,NA,Colon and Rectal Cancer,Gastrointestinal Cancers,FOLFOX4,NA,0.68 (0.54-0.87),4,20.9 months,7.4 months,0.74 (0.57-0.96),9.2 months,1.6 months,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Panitumumab,mFOLFOX6,Bevacizumab + mFOLFOX6    (Randomised phase II study with unbalanced crossover),1st line metastatic CRC,Gastrointestinal Cancers,Colon and Rectal Cancer,RAS/BRAF-WT,Metastatic,3,NA,NA,http://ascopubs.org/doi/abs/10.1200/JCO.2013.53.2473?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,https://link.springer.com/article/10.1007%2Fs00384-017-2800-1,NA,Bevacizumab + mFOLFOX6    (Randomised phase II study with unbalanced crossover) ,NA,NA,NA,NA,Form 2b,PFS,1st line metastatic CRC,PEAK,            Metastatic    ,RAS/BRAF-WT,Colon and Rectal Cancer,Gastrointestinal Cancers,mFOLFOX6,NA,0.61 (0.42-0.88),3,28.9 months,12.4 months,0.70 (0.48-1.04) NEB,10.1 months,3 months,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Cetuximab,FOLFIRI,FOLFIRI,"1st line metastatic (post hoc KRAS, NRAS WT)",Gastrointestinal Cancers,Colon and Rectal Cancer,RAS-WT,Metastatic,4,NA,NA,http://ascopubs.org/doi/abs/10.1200/JCO.2014.59.4812?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,NA,NA,FOLFIRI ,NA,NA,NA,NA,Form 2a,PFS,"1st line metastatic (post hoc KRAS, NRAS WT)",CRYSTAL,            Metastatic    ,RAS-WT,Colon and Rectal Cancer,Gastrointestinal Cancers,FOLFIRI,NA,0.56 (0.41-0.76),4,20.2 months,8.2 months,0.69 (0.54-0.88),8.4 months,3 months,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Cetuximab,-,Best supportive care,Refractory metastatic KRAS-WT,Gastrointestinal Cancers,Colon and Rectal Cancer,KRAS-WT,Metastatic,4,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa0804385?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA,Best supportive care,NA,NA,NA,NA,Form 2a,OS,Refractory metastatic KRAS-WT,NA,            Metastatic    ,KRAS-WT,Colon and Rectal Cancer,Gastrointestinal Cancers,NA,NA,0.40 (0.30-0.54),4,4.8 months,4.7 months,0.55 (0.41-0.74),1.9 months,1.8 months,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Bevacizumab,IFL,IFL + placebo,1st line metastatic,Gastrointestinal Cancers,Colon and Rectal Cancer,-,Metastatic,3,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa032691?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA,IFL + placebo,NA,NA,NA,NA,Form 2a,OS,1st line metastatic,NA,            Metastatic    ,NA,Colon and Rectal Cancer,Gastrointestinal Cancers,IFL,NA,NA,3,15.6 months,4.7 months,0.66 (0.54-0.81),NA,NA,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Panitumumab,FOLFIRI,FOLFIRI,2nd line metastatic,Gastrointestinal Cancers,Colon and Rectal Cancer,RAS-WT,Metastatic,3,NA,NA,http://ascopubs.org/doi/abs/10.1200/JCO.2009.27.6055?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,http://clincancerres.aacrjournals.org/content/21/24/5469.long,NA,FOLFIRI ,NA,NA,NA,NA,Form 2b,PFS and OS,2nd line metastatic ,NA,            Metastatic    ,RAS-WT,Colon and Rectal Cancer,Gastrointestinal Cancers,FOLFIRI,NA,0.70 (0.54-0.91),3,13.9 months,2.3 months,0.81 (0.63-1.03) NEB,4.6 months,1.8 months,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Ramucirumab,FOLFIRI,FOLFIRI + placebo,"2nd line metastatic after bevacizumab, oxaliplatin, fluoropyrimidine",Gastrointestinal Cancers,Colon and Rectal Cancer,-,Metastatic,1,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70127-0/fulltext,NA,NA,FOLFIRI + placebo,NA,NA,NA,NA,Form 2a,OS,"2nd line metastatic after bevacizumab, oxaliplatin, fluoropyrimidine",RAISE,            Metastatic    ,NA,Colon and Rectal Cancer,Gastrointestinal Cancers,FOLFIRI,NA,NA,1,11.7 months,"1.6 months, 2-year survival advantage 5-10%",0.84 (0.73-0.97),NA,NA,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Bevacizumab,FOLFOX4,FOLFOX4,2nd line metastatic after FOLFIRI,Gastrointestinal Cancers,Colon and Rectal Cancer,-,Metastatic,3,NA,NA,http://ascopubs.org/doi/abs/10.1200/JCO.2006.09.6305?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,NA,NA,FOLFOX4  ,NA,NA,NA,NA,Form 2a,OS,2nd line metastatic after FOLFIRI,E3200,            Metastatic    ,NA,Colon and Rectal Cancer,Gastrointestinal Cancers,FOLFOX4,NA,NA,3,10.8 months,2.1 months,0.75 (0.63-0.89),NA,NA,3,NA,NA,04.08.2020,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Panitumumab,-,Best supportive care,3rd line metastatic,Gastrointestinal Cancers,Colon and Rectal Cancer,RAS-WT,Metastatic,3,NA,NA,http://clincancerres.aacrjournals.org/content/19/7/1902,http://ascopubs.org/doi/abs/10.1200/jco.2013.31.15_suppl.3617,NA,Best supportive care,NA,NA,NA,NA,Form 2b,PFS,3rd line metastatic,NA,            Metastatic    ,RAS-WT,Colon and Rectal Cancer,Gastrointestinal Cancers,NA,NA,0.36 (0.25-0.52),3,NA,NA,NA,7 weeks,7.1 weeks,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Oxaliplatine,"5FU, Irinotecan, Bevacizumab",FOLFIRI bevacizumab,1st line metastatic,Gastrointestinal Cancers,Colon and Rectal Cancer,-,Metastatic,2,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1403108?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00122-9/fulltext,NA,FOLFIRI bevacizumab ,NA,NA,NA,NA,Form 2a,PFS,1st line metastatic,TRIBE,            Metastatic    ,NA,Colon and Rectal Cancer,Gastrointestinal Cancers,"5FU, Irinotecan, Bevacizumab",NA,0.75 (0.62-0.90),2,25.8 months,4 months,0.80 (0.65-0.98),9.7 months,2.4 months,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Trifluiridine/tipiracil (TAS-102),-,Placebo,3rd line metastatic CRC,Gastrointestinal Cancers,Colon and Rectal Cancer,-,Metastatic,2,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1414325?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA,Placebo,NA,NA,NA,NA,Form 2a,OS,3rd line metastatic CRC ,RECOURSE,            Metastatic    ,NA,Colon and Rectal Cancer,Gastrointestinal Cancers,NA,NA,NA,2,5.3 months,1.8 months,0.68 (0.58-0.81),NA,NA,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Regorafenib,-,Placebo,3rd line metastatic,Gastrointestinal Cancers,Colon and Rectal Cancer,-,Metastatic,1,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61900-X/fulltext,NA,NA,Placebo,NA,NA,NA,NA,Form 2a,OS,3rd line metastatic,CORRECT,            Metastatic    ,NA,Colon and Rectal Cancer,Gastrointestinal Cancers,NA,NA,NA,1,5 months,1.4 months,0.77 (0.64-0.94),NA,NA,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Aflibercept,FOLFIRI,FOLFIRI + placebo,2nd line after oxaliplatin based treatment,Gastrointestinal Cancers,Colon and Rectal Cancer,-,Metastatic,1,NA,NA,http://ascopubs.org/doi/abs/10.1200/JCO.2012.42.8201?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,NA,NA,FOLFIRI + placebo,NA,NA,NA,NA,Form 2a,OS,2nd line after oxaliplatin based treatment,VELOUR,            Metastatic    ,NA,Colon and Rectal Cancer,Gastrointestinal Cancers,FOLFIRI,NA,0.76 (0.66-0.87),1,12.1 months,1.4 months,0.82 (0.71-0.94),4.7 months,2.2 months,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Bevacizumab,Chemotherapy,Chemotherapy,2nd line beyond progression on bevacizumab,Gastrointestinal Cancers,Colon and Rectal Cancer,-,Metastatic,1,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70477-1/fulltext,NA,NA,Chemotherapy,NA,NA,NA,NA,Form 2a,OS,2nd line beyond progression on bevacizumab,MI18147,            Metastatic    ,NA,Colon and Rectal Cancer,Gastrointestinal Cancers,Chemotherapy,NA,NA,1,9.8 months,1.4 months,0.81 (0.69-0.94),NA,NA,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Epirubicin, 5FU, Cisplatin",-,Surgery,Peri-operative,Gastrointestinal Cancers,Oesophageal or Gastric Cancer,-,Early,A,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa055531?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA,Surgery ,NA,NA,NA,A,Form 1,OS,Peri-operative,MAGIC,            Early    ,NA,Oesophageal or Gastric Cancer,Gastrointestinal Cancers,NA,NA,NA,NA,5-year survival 23%,13 %,0.66 (0.53-0.81),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"5FU, Cisplatin",-,Surgery,Peri-operative,Gastrointestinal Cancers,Oesophageal or Gastric Cancer,-,Early,A,NA,NA,http://ascopubs.org/doi/abs/10.1200/JCO.2010.33.0597?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,NA,NA,Surgery ,NA,NA,NA,A,Form 1,OS,Peri-operative,NA,            Early    ,NA,Oesophageal or Gastric Cancer,Gastrointestinal Cancers,NA,NA,NA,NA,5-year survival 24%,14 %,0.69 (0.50-0.95),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Ramucirumab,Paclitaxel,Paclitaxel + placebo,2nd line advanced or metastatic gastric or EGJ adenocarcinoma,Gastrointestinal Cancers,Gastric or gastro-oesophageal junction cancer,-,Metastatic,2,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70420-6/fulltext,NA,NA,Paclitaxel + placebo,NA,NA,NA,NA,Form 2a,OS,2nd line advanced or metastatic gastric or EGJ adenocarcinoma,RAINBOW,            Metastatic    ,NA,Gastric or gastro-oesophageal junction cancer,Gastrointestinal Cancers,Paclitaxel,NA,NA,2,7.4 months,2.2 months,0.81 (0.68-0.96),NA,NA,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Ramucirumab,-,Placebo,2nd line gastro-oesophageal or gastric cancer after cisplatin/5-FU,Gastrointestinal Cancers,Oesophageal Cancer,-,Metastatic,1,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)61719-5/fulltext,NA,NA,Placebo,NA,NA,NA,NA,Form 2a,OS,2nd line gastro-oesophageal or gastric cancer after cisplatin/5-FU,REGARD,            Metastatic    ,NA,Oesophageal Cancer,Gastrointestinal Cancers,NA,NA,NA,1,3.8 months,1.4 months,0.78 (0.60 - 0.99),NA,NA,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
FOLFIRINOX,-,Gemcitabine,1st line advanced or metastatic. Good performance status,Gastrointestinal Cancers,Pancreatic cancer,-,Metastatic,5,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1011923?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA,Gemcitabine,NA,NA,NA,NA,Form 2a,OS (crossover allowed),1st line advanced or metastatic. Good performance status,NA,            Metastatic    ,NA,Pancreatic cancer,Gastrointestinal Cancers,NA,NA,NA,5,6.8 months,4.3 months,0.57 (0.45-0.73),NA,NA,4,1+,Delayed deterioration,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Nab-paclitaxel,Gemcitabine,Gemcitabine,1st line advanced or metastatic. Good performance status (KPS>70%),Gastrointestinal Cancers,Pancreatic cancer,-,Metastatic,2,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1304369?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA,Gemcitabine,NA,NA,NA,NA,Form 2a,OS,1st line advanced or metastatic. Good performance status (KPS>70%),NA,            Metastatic    ,NA,Pancreatic cancer,Gastrointestinal Cancers,Gemcitabine,NA,NA,2,6.7 months 2-years survival 4%,1.8 months 2-year survival gain 5%,0.72 (0.62-0.83),NA,NA,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Erlotinib,Gemcitabine,Gemcitabine + placebo,1st line advanced or metastatic,Gastrointestinal Cancers,Pancreatic cancer,-,Metastatic,1,NA,NA,http://ascopubs.org/doi/abs/10.1200/JCO.2006.07.9525?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,NA,NA,Gemcitabine + placebo,NA,NA,NA,NA,Form 2a,OS,1st line advanced or metastatic,NA,            Metastatic    ,NA,Pancreatic cancer,Gastrointestinal Cancers,Gemcitabine,NA,NA,1,5.9 months,0.3 months,0.82 (0.69-0.99),NA,NA,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Bevacizumab,Combination chemotherapy,Combination chemotherapy,"Recurrent, persistent or metastatic cervical cancer",Gynaecological Malignancies,Cervical Cancer,-,Metastatic,3,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1309748?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA,Combination chemotherapy,NA,NA,NA,NA,Form 2a,OS,"Recurrent, persistent or metastatic cervical cancer",NA,            Metastatic    ,NA,Cervical Cancer,Gynaecological Malignancies,Combination chemotherapy,NA,NA,3,13.3 months,3.7 months,0.71 (0.54-0.95),NA,NA,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Bevacizumab,Chemotherapy,Paclitaxel or topotecan or liposomal doxorubicin,Recurrent platinum-resistant ovarian cancer,Gynaecological Malignancies,Ovarian Cancer,-,Metastatic,4,NA,NA,http://ascopubs.org/doi/pdf/10.1200/JCO.2013.51.4240,http://ascopubs.org/doi/pdf/10.1200/JCO.2013.51.4489,NA,Paclitaxel or topotecan or liposomal doxorubicin ,NA,NA,NA,NA,Form 2b,PFS (crossover allowed),Recurrent platinum-resistant ovarian cancer,AURELIA,            Metastatic    ,NA,Ovarian Cancer,Gynaecological Malignancies,Chemotherapy,NA,0.48 (0.38-0.60),4,NA,NA,NS,3.4 months,3.3 months,3,1+,Improved,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Bevacizumab,Paclitaxel + carboplatin,Paclitaxel + carboplatin,Early stage post-resection advanced ovarian or primary peritoneal ALL,Gynaecological Malignancies,Ovarian Cancer,-,Early,1,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70567-3/fulltext,https://www.nejm.org/doi/10.1056/NEJMoa1103799?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,Paclitaxel + carboplatin ,NA,NA,NA,NA,Form 2b,PFS stratified for stage and risk of progression   (All) ,Early stage post-resection advanced ovarian or primary peritoneal ALL,ICON7,            Early    ,NA,Ovarian Cancer,Gynaecological Malignancies,Paclitaxel + carboplatin,NA,0.87 (0.77-0.99),1,NA,NA,NS,17.4 months,2.4 months       ,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Bevacizumab,Paclitaxel + carboplatin,Paclitaxel + carboplatin,Early stage post-resection advanced ovarian or primary peritoneal High risk,Gynaecological Malignancies,Ovarian Cancer,-,Early,3,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70567-3/fulltext,https://www.nejm.org/doi/10.1056/NEJMoa1103799?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,Paclitaxel + carboplatin ,NA,NA,NA,NA,Form 2a,PFS stratified for stage and risk of progression          (High risk) , Early stage post-resection advanced ovarian or primary peritoneal High risk,ICON7,            Early    ,NA,Ovarian Cancer,Gynaecological Malignancies,Paclitaxel + carboplatin,NA,0.73 (0.60-0.93),3,28.8 months ,7.8 months,0.64 (0.48-0.85),10.5 months,5.5 months,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Bevacizumab,Gemcitabine + carboplatin,Gemcitabine + carboplatin,Recurrent platinum-sensitive ovarian cancer,Gynaecological Malignancies,Ovarian Cancer,-,Metastatic,3,NA,NA,http://ascopubs.org/doi/abs/10.1200/JCO.2012.42.0505?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,NA,NA,Gemcitabine + carboplatin,NA,NA,NA,NA,Form 2b,PFS (crossover allowed),Recurrent platinum-sensitive ovarian cancer,OCEANS,            Metastatic    ,NA,Ovarian Cancer,Gynaecological Malignancies,Gemcitabine + carboplatin,NA,0.48 (0.39-0.61),3,NA,NA,NS,8.4 months,4 months,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Bevacizumab,Carboplatin + paclitaxel,Paclitaxel and carboplatin (6 cycles),Incompletely resected stage III and stage IV ovarian cancer,Gynaecological Malignancies,Ovarian Cancer,-,Metastatic,3,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1104390?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA,Paclitaxel and carboplatin (6 cycles) ,NA,NA,NA,NA,Form 2b,PFS (crossover allowed),Incompletely resected stage III and stage IV ovarian cancer,GOG 218,            Metastatic    ,NA,Ovarian Cancer,Gynaecological Malignancies,Carboplatin + paclitaxel,NA,0.72 (0.63-0.82),3,NA,NA,NS,10.3 months,Bevacizumab continuation 3.8 months,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Niraparib,-,Placebo,Maintenance,Gynaecological Malignancies,Ovarian Cancer,gBRCA,Metastatic,3,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1611310?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA, Placebo,NA,NA,NA,NA,Form 2b,PFS,Maintenance  ,ENGOT-OV16/NOVA,            Metastatic    ,gBRCA,Ovarian Cancer,Gynaecological Malignancies,NA,NA,0.27 (0.17-0.41),3,NA,NA,NA,5.5 months,15.5 months,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Niraparib,-,Placebo,Maintenance,Gynaecological Malignancies,Ovarian Cancer,non-gBRCA HRD +ve,Metastatic,3,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1611310?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA, Placebo,NA,NA,NA,NA,Form 2b,PFS,Maintenance  ,ENGOT-OV16/NOVA,            Metastatic    ,non-gBRCA HRD +ve,Ovarian Cancer,Gynaecological Malignancies,NA,NA,0.38 (0.24-0.59),3,NA,NA,NA,3.8 months,9.1 months,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Niraparib,-,Placebo,Maintenance,Gynaecological Malignancies,Ovarian Cancer,non-gBRCA,Metastatic,3,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1611310?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA, Placebo,NA,NA,NA,NA,Form 2b,PFS,Maintenance  ,ENGOT-OV16/NOVA,            Metastatic    ,non-gBRCA,Ovarian Cancer,Gynaecological Malignancies,NA,NA,0.45 (0.34-0.61),3,NA,NA,NA,3.9 months,5.4 months,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Trabectedin,Pegylated liposomal doxorubicin,Pegylated liposomal doxorubicin,2nd line metastatic ovarian cancer (Platine sensitive),Gynaecological Malignancies,Ovarian Cancer,-,Metastatic,2,NA,NA,http://ascopubs.org/doi/abs/10.1200/JCO.2009.25.4037?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,NA,NA,Pegylated liposomal doxorubicin,NA,NA,NA,NA,Form 2b,PFS stratified for platinum sensivity/resistance                 (Sensitive) ,2nd line metastatic ovarian cancer (Platine sensitive),OVA-301,            Metastatic    ,NA,Ovarian Cancer,Gynaecological Malignancies,Pegylated liposomal doxorubicin,NA,0.73 (0.56-0.95),2,NA,NA,NA,7.5 months,1.7 months,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Trabectedin,Pegylated liposomal doxorubicin,Pegylated liposomal doxorubicin,2nd line metastatic ovarian cancer (All),Gynaecological Malignancies,Ovarian Cancer,-,Metastatic,3,NA,NA,http://ascopubs.org/doi/abs/10.1200/JCO.2009.25.4037?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,NA,NA,Pegylated liposomal doxorubicin,NA,NA,NA,NA,Form 2b,PFS stratified for platinum sensivity/resistance                   (All),2nd line metastatic ovarian cancer (All),OVA-302,            Metastatic    ,NA,Ovarian Cancer,Gynaecological Malignancies,Pegylated liposomal doxorubicin,NA,0.79 (0.65-0.96),3,NA,NA,NA,5.8 months,1.5 months,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Olaparib,-,Placebo,Maintenance (Randomised phase II study),Gynaecological Malignancies,Ovarian Cancer,BRCA mutation,Metastatic,3,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1105535?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70228-1/fulltext,https://www.nature.com/articles/bjc2016348,Placebo,NA,NA,NA,NA,Form 2b,PFS,Maintenance (Randomised phase II study),Study 19,            Metastatic    ,BRCA mutation,Ovarian Cancer,Gynaecological Malignancies,NA,NA,0.18 (0.10-0.31),3,27.8 months,2 months,0.73 (0.55-0.96),4.3 months,6.9 months,3,NA,Not improved,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Cediranib,Chemotherapy,Platinum-based chemotherapy + placebo and placebo maintenance,Platinum-sensitive relapsed ovarian cancer,Gynaecological Malignancies,Ovarian Cancer,-,Metastatic,1,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01167-8/fulltext,NA,NA,Platinum-based chemotherapy + placebo and placebo maintenance,NA,NA,NA,NA,Form 2b,PFS,Platinum-sensitive relapsed ovarian cancer,ICON 6,            Metastatic    ,NA,Ovarian Cancer,Gynaecological Malignancies,Chemotherapy,NA,0.56 (0.44-0.72),1,NA,NA,NS,8.7 months,2.3 months,2,NA,NA,NA,1-,25-35% discontinuation B/C toxicity >5% increase grade 3/4 fatigue,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Nivolumab,-,Chemotherapy,Platinum-refractory metastatic H+N squamous cell cancer,Head and neck cancer,Squamous cell,-,Metastatic,4,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1602252?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA,Chemotherapy,NA,NA,NA,NA,Form 2a,OS - All,Platinum-refractory metastatic H+N squamous cell cancer,CheckMate 141,            Metastatic    ,NA,Squamous cell,Head and neck cancer,NA,NA,NA,4,5.1 months,2.4 months,0.69 (0.53-0.91),NA,NA,3,1+,Improved,NA,NA,Reduced,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Nivolumab,-,Chemotherapy,Platinum-refractory metastatic H+N squamous cell cancer stratified for PD-L1,Head and neck cancer,Squamous cell,-,Metastatic,5,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1602252?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA,Chemotherapy,NA,NA,NA,NA,Form 2a,OS - PD-L1 >1%,Platinum-refractory metastatic H+N squamous cell cancer stratified for PD-L1,CheckMate 141,            Metastatic    ,NA,Squamous cell,Head and neck cancer,NA,NA,NA,5,4.6 months,4.1 months,0.55 (0.36-0.83),NA,NA,4,1+,Improved,NA,NA,Reduced,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Pembrolizumab,-,Docetaxel,2nd line after platinum-based therapy OR TKI (for EGFR/ALK Mutated) advanced NSCLC>1% tumour cell PD-L1 expression (all) Pembro 2mg/kg,Thoracic Malignancies,Non-small-cell Lung Cancer,-,Metastatic,5,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01281-7/fulltext,NA,NA,Docetaxel,NA,NA,NA,NA,Form 2a,OS - All >1%  - 2mg/kg,2nd line after platinum-based therapy OR TKI (for EGFR/ALK Mutated) advanced NSCLC>1% tumour cell PD-L1 expression (all) Pembro 2mg/kg,KEYNOTE-010,            Metastatic    ,NA,Non-small-cell Lung Cancer,Thoracic Malignancies,NA,NA,NA,5,8.5 months ,1.9 months ,0.71 (0.58-0.88) ,NA,NA,4,NA,NA,16.03.2020,1+,Reduce grade 3/4 adverse events 13/16% vs 35,2-year survival gain >10%,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Pembrolizumab,-,Docetaxel,2nd line after platinum-based therapy OR TKI (for EGFR/ALK Mutated) advanced NSCLC>1% tumour cell PD-L1 expression (all) Pembro 10mg/kg,Thoracic Malignancies,Non-small-cell Lung Cancer,-,Metastatic,5,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01281-7/fulltext,NA,NA,Docetaxel,NA,NA,NA,NA,Form 2a,OS - All >1%          10 mg/kg,2nd line after platinum-based therapy OR TKI (for EGFR/ALK Mutated) advanced NSCLC>1% tumour cell PD-L1 expression (all) Pembro 10mg/kg,KEYNOTE-010,            Metastatic    ,NA,Non-small-cell Lung Cancer,Thoracic Malignancies,NA,NA,NA,5,8.5 months ,4.2 months,0.61 (0.49-0.75),NA,NA,4,NA,NA,NA,1+,Reduce grade 3/4 adverse events 13/16% vs 36,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Pembrolizumab,-,Docetaxel,2nd line after platinum-based therapy OR TKI (for EGFR/ALK Mutated) advanced NSCLC >50% tumour cell PD-L1 expression Pembro 2mg/kg,Thoracic Malignancies,Non-small-cell Lung Cancer,-,Metastatic,5,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01281-7/fulltext,NA,NA,Docetaxel,NA,NA,NA,NA,Form 2a,OS - >50%      2 mg/kg,2nd line after platinum-based therapy OR TKI (for EGFR/ALK Mutated) advanced NSCLC >50% tumour cell PD-L1 expression Pembro 2mg/kg,KEYNOTE-010,            Metastatic    ,NA,Non-small-cell Lung Cancer,Thoracic Malignancies,NA,NA,NA,5,8.2 months,6.7 months,0.54 (0.38-0.77),NA,NA,4,NA,NA,NA,1+,Reduce grade 3/4 adverse events 13/16% vs 37,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Pembrolizumab,-,Docetaxel,2nd line after platinum-based therapy OR TKI (for EGFR/ALK Mutated) advanced NSCLC>50% tumour cell PD-L1 expression Pembro 10mg/kg,Thoracic Malignancies,Non-small-cell Lung Cancer,-,Metastatic,5,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01281-7/fulltext,NA,NA,Docetaxel,NA,NA,NA,NA,Form 2a,OS - >50%    10 mg/kg,2nd line after platinum-based therapy OR TKI (for EGFR/ALK Mutated) advanced NSCLC>50% tumour cell PD-L1 expression Pembro 10mg/kg,KEYNOTE-010,            Metastatic    ,NA,Non-small-cell Lung Cancer,Thoracic Malignancies,NA,NA,NA,5,8.2 months,9.1 months,0.50 (0.36-0.70),NA,NA,4,NA,NA,NA,1+,Reduce grade 3/4 adverse events 13/16% vs 37,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Nivolumab,-,Docetaxel,2nd line after platinum-based therapy advanced squamous-cell NSCLC,Thoracic Malignancies,Non-small-cell Lung Cancer,Squamous cell,Metastatic,5,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1504627?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA,Docetaxel,NA,NA,NA,NA,Form 2a,OS,2nd line after platinum-based therapy advanced squamous-cell NSCLC ,CheckMate 017,            Metastatic    , Squamous cell,Non-small-cell Lung Cancer,Thoracic Malignancies,NA,NA,0.62 (0.47-0.81),5,6 months,3.2 months 2-year survival gain:15%,0.59 (0.44-0.79),2.8 months,0.7 months,4,NA,NA,NA,1+,Reduced grade 3/4 AE 7% vs 55%,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Nivolumab,-,Docetaxel,2nd line after platinum-based therapy advanced non-squamous-cell NSCLC stratified for PD-L1,Thoracic Malignancies,Non-small-cell Lung Cancer,Non-squamous cell,Metastatic,5,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1507643?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,https://www.jto.org/article/S1556-0864(16)30815-2/fulltext,NA,Docetaxel,NA,NA,NA,NA,Form 2a,OS,2nd line after platinum-based therapy advanced non-squamous-cell NSCLC stratified for PD-L1,CheckMate 057,            Metastatic    ,Non-squamous cell,Non-small-cell Lung Cancer,Thoracic Malignancies,NA,NA,NA,5,9.4 months,2.8 months 2-year survival gain >10%,0.73 (0.59-0.89),NA,NA,4,NA,Improved,NA,1+,Reduced grade 3/4 AE10% vs 54%,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Erlotinib,-,Carboplatin gemcitabine,"1st line stage III or IV non-squamous, with EGFR mutation",Thoracic Malignancies,Non-small-cell Lung Cancer,EGFR+,Metastatic,4,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70184-X/fulltext,NA,NA,Carboplatin gemcitabine,NA,NA,NA,NA,Form 2b,PFS,"1st line stage III or IV non-squamous, with EGFR mutation","OPTIMAL, CTONG-0802",            Metastatic    ,EGFR+,Non-small-cell Lung Cancer,Thoracic Malignancies,NA,NA,0.16 (0.10-0.26),4,NA,NA,NA,4.6 months,8.5 months,3,NA,NA,NA,1+,12% less serious adverse events,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Erlotinib,-,Platinum-based chemotherapy doublet,"1st line stage III or IV non-squamous, with EGFR mutation",Thoracic Malignancies,Non-small-cell Lung Cancer,EGFR+,Metastatic,4,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70393-X/fulltext,NA,NA,Platinum-based chemotherapy doublet,NA,NA,NA,NA,Form 2b,PFS (crossover allowed),"1st line stage III or IV non-squamous, with EGFR mutation",EURTAC,            Metastatic    ,EGFR+,Non-small-cell Lung Cancer,Thoracic Malignancies,NA,NA,0.37 (0.25-0.54),4,19.35 months,NA,NS,5.2 months,4.5 months,3,NA,NA,NA,1+,15% less severe adverse reactions,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Gefitinib,-,Carboplatin + paclitaxel,1st line stage III or IV adenocarcinoma with EGFR mutation,Thoracic Malignancies,Non-small-cell Lung Cancer,EGFR+,Metastatic,4,NA,NA,http://ascopubs.org/doi/abs/10.1200/JCO.2010.33.4235?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,https://www.nejm.org/doi/10.1056/NEJMoa0810699?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,Carboplatin + paclitaxel,NA,NA,NA,NA,Form 2b,PFS (crossover allowed),1st line stage III or IV adenocarcinoma with EGFR mutation,IPASS,            Metastatic    ,EGFR+,Non-small-cell Lung Cancer,Thoracic Malignancies,NA,NA,0.48 (0.34-0.67),4,NA,NA,NA,6.3 months,3.3 months,3,NA,Improved,NA,1+,Reduced toxicity,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Afatinib,-,Cisplatin + pemetrexed,1st line stage III or IV adenocarcinoma with EGFR mutation,Thoracic Malignancies,Non-small-cell Lung Cancer,EGFR+,Metastatic,4,NA,NA,http://ascopubs.org/doi/abs/10.1200/JCO.2012.44.2806?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,http://ascopubs.org/doi/abs/10.1200/JCO.2012.46.1764?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,NA,Cisplatin + pemetrexed,NA,NA,NA,NA,Form 2b,PFS (crossover allowed),1st line stage III or IV adenocarcinoma with EGFR mutation,LUX - Lung 3,            Metastatic    ,EGFR+,Non-small-cell Lung Cancer,Thoracic Malignancies,NA,NA,0.58 (0.43-0.78),4,NA,NA,NA,6.9 months,4.2 months,3,1+,Improved,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Afatinib,-,Cisplatin + pemetrexed,1st line stage III or IV adenocarcinoma with EGFR mutation                                  (Del19/L858R),Thoracic Malignancies,Non-small-cell Lung Cancer,EGFR+,Metastatic,4,NA,NA,http://ascopubs.org/doi/abs/10.1200/JCO.2012.44.2806?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,http://ascopubs.org/doi/abs/10.1200/JCO.2012.46.1764?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,NA,Cisplatin + pemetrexed,NA,NA,NA,NA,Form 2b,PFS,1st line stage III or IV adenocarcinoma with EGFR mutation                                  (Del19/L858R),LUX - Lung 3,            Metastatic    ,EGFR+,Non-small-cell Lung Cancer,Thoracic Malignancies,NA,NA,0.47 (0.34-0.65),4,NA,NA,NA,6.9 months,6.7 months,3,1+,Improved,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Osimertinib,-,Platinum/pemetrexed,2nd line for EGFR mutated NSCLC after TKI with new T790M mutation,Thoracic Malignancies,Non-small-cell Lung Cancer,EGFR+,Advanced,4,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1612674?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,https://ascopubs.org/doi/full/10.1200/JCO.2017.77.2293?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,NA,Platinum/pemetrexed,NA,NA,NA,NA,Form 2b,PFS (crossover allowed),2nd line for EGFR mutated NSCLC after TKI with new T790M mutation,AURA3,            Advanced    ,EGFR+,Non-small-cell Lung Cancer,Thoracic Malignancies,NA,NA,0.30 (0.23-0.41),4,NA,NA,NA,4.4 months,5.7 months,3,NA,Improved patient reported outcomes,30.04.2020,1+,Reduced toxicity,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Crizotinib,-,Chemotherapy,"2nd line stage III or IV non-squamous, with ALK mutation",Thoracic Malignancies,Non-small-cell Lung Cancer,ALK+,Metastatic,4,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1214886?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA,Chemotherapy,NA,NA,NA,NA,Form 2b,PFS (crossover allowed),"2nd line stage III or IV non-squamous, with ALK mutation",PROFILE 1007,            Metastatic    ,ALK+,Non-small-cell Lung Cancer,Thoracic Malignancies,NA,NA,0.49 (0.37-0.64),4,NA,NA,NA,3.0 months,4.7 months,3,1+,Improved,NA,NA,1% increased toxic death,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Crizotinib,-,Pemetrexed + cisplatin or carboplatin,"1st line stage III or IV non-squamous, with ALK mutation",Thoracic Malignancies,Non-small-cell Lung Cancer,ALK+,Metastatic,4,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1408440?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA,Pemetrexed + cisplatin or carboplatin,NA,NA,NA,NA,Form 2b,PFS (crossover allowed),"1st line stage III or IV non-squamous, with ALK mutation",PROFILE 1014,            Metastatic    ,ALK+,Non-small-cell Lung Cancer,Thoracic Malignancies,NA,NA,0.45 (0.35-0.60),4,NA,NA,NA,7.0 months,3.9 months,3,1+,Improved,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Pemetrexed,-,Placebo,Stage III or IV disease maintenance after responding to 4 cycles platinum doublet,Thoracic Malignancies,Non-small-cell Lung Cancer,-,Metastatic,4,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61497-5/fulltext,NA,NA,Placebo,NA,NA,NA,NA,Form 2a,PFS stratified for histology (non-squamous),Stage III or IV disease maintenance after responding to 4 cycles platinum doublet,NA,            Metastatic    ,NA,Non-small-cell Lung Cancer,Thoracic Malignancies,NA,NA,0.50 (0.42-0.61),4,10.3 months,5.2 months,0.70 (0.56-0.88),2.6 months,1.7 months,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Pemetrexed,Cisplatin,Cisplatin + gemcitabine,1st line stage III or IV (non-squamous),Thoracic Malignancies,Non-small-cell Lung Cancer,-,Metastatic,4,NA,NA,http://ascopubs.org/doi/abs/10.1200/JCO.2007.15.0375?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,NA,NA,Cisplatin + gemcitabine,NA,NA,NA,NA,Form 2a,OS (non-inferiority),1st line stage III or IV (non-squamous),NA,            Metastatic    ,NA,Non-small-cell Lung Cancer,Thoracic Malignancies,Cisplatin,NA,NA,4,10.4 months,1.4 months,0.81 (0.70-0.94),NA,NA,3,NA,NA,NA,1+,Less grade 3+ toxicity: neutropenia anaemia thrombocytopenia,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Palliative care,Chemotherapy,Chemotherapy,1st line treatment stage IV NSCLC ECOG<2,Thoracic Malignancies,Non-small-cell Lung Cancer,-,Metastatic,4,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1000678?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA,Chemotherapy ,NA,NA,NA,NA,Form 2c,QoL,1st line treatment stage IV NSCLC ECOG<2,NA,            Metastatic    ,NA,Non-small-cell Lung Cancer,Thoracic Malignancies,Chemotherapy,NA,NA,4,8.9 months,2.7 months,HR for death in control arm 1.7 (1.14-2.54),NA,NA,4,NA,Improved,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Pembrolizumab,-,Platinum-based chemotherapy,1st line metastatic and advanced NSCLC with PD-L1>50%,Thoracic Malignancies,Non-small-cell Lung Cancer,-,Metastatic and advanced,5,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1606774?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,https://www.sciencedirect.com/science/article/abs/pii/S1470204517306903,https://ascopubs.org/doi/10.1200/JCO.18.00149?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed,Platinum-based chemotherapy,NA,NA,NA,NA,Form 2a,PFS,1st line metastatic and advanced NSCLC with PD-L1>50%,KEYNOTE-24,            Metastatic and advanced    ,NA,Non-small-cell Lung Cancer,Thoracic Malignancies,NA,NA,0.50 (0.37-0.68),5,14.2 months,15.8 months,0.63 (0.47-0.86),6 months,4.3 months,4,NA,NA,15.09.2020,1+,Improved toxicity profile,NA,OS,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Bevacizumab,Erlotinib,Erlotinib,1st line therapy,Thoracic Malignancies,Non-small-cell Lung Cancer,EGFR+,Advanced,3,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70381-X/fulltext,NA,NA,Erlotinib ,NA,NA,NA,NA,Form 2b,PFS (Phase II study),1st line therapy ,NA,            Advanced    ,EGFR+,Non-small-cell Lung Cancer,Thoracic Malignancies,Erlotinib,NA,0.54 (0.36-0.79),3,NA,NA,NA,9.7 months,6.3 months,3,NA,No improvement in QoL,NA,NA,Deteriorated toxicity profile not reaching the toxicity thresholds for penalty,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Afatinib,-,Erlotinib,2nd line treatment of patients with advanced SCC who had progressed on platinum-based doublet chemotherapy,Thoracic Malignancies,Non-small-cell Lung Cancer,Squamous cell,Metastatic,2,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00006-6/fulltext,https://www.clinical-lung-cancer.com/article/S1525-7304(17)30175-4/fulltext,NA,Erlotinib,NA,NA,NA,NA,Form 2a,OS,2nd line treatment of patients with advanced SCC who had progressed on platinum-based doublet chemotherapy,LUX - Lung 8,            Metastatic    ,Squamous cell,Non-small-cell Lung Cancer,Thoracic Malignancies,NA,NA,NA,2,6.8 months,1.1 month,0.81 (0.69-0.95),NA,NA,1,1+,Improved,06.11.2019 - 2018 article added,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Bevacizumab,Paclitaxel + carboplatin,Paclitaxel + carboplatin,"1st line stage III or IV, non-squamous",Thoracic Malignancies,Non-small-cell Lung Cancer,-,Metastatic,2,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa061884?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA,Paclitaxel + carboplatin,NA,NA,NA,NA,Form 2a,OS,"1st line stage III or IV, non-squamous",NA,            Metastatic    ,NA,Non-small-cell Lung Cancer,Thoracic Malignancies,Paclitaxel + carboplatin,NA,NA,2,10.3 months,2 months,0.79 (0.67-0.92),NA,NA,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Ramucirumab,Docetaxel,Docetaxel + placebo,2nd line after platinum-based therapy NSCLC,Thoracic Malignancies,Non-small-cell Lung Cancer,-,Metastatic,1,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)60845-X/fulltext,NA,NA,Docetaxel + placebo,NA,NA,NA,NA,Form 2a,OS,2nd line after platinum-based therapy NSCLC,REVEL,            Metastatic    ,NA,Non-small-cell Lung Cancer,Thoracic Malignancies,Docetaxel,NA,NA,1,9.1 months,1.4 months,0.86 (0.75-0.98),NA,NA,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Necitumumab,Gemcitabine + cisplatin,Gemcitabine + cisplatin,1st line treatment of patients with stage IV metastatic squamous NSCLC,Thoracic Malignancies,Non-small-cell Lung Cancer,Squamous cell,Metastatic,1,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00021-2/fulltext,NA,NA,Gemcitabine + cisplatin,NA,NA,NA,NA,Form 2a,OS,1st line treatment of patients with stage IV metastatic squamous NSCLC ,SQUIRE,            Metastatic    ,Squamous cell,Non-small-cell Lung Cancer,Thoracic Malignancies,Gemcitabine + cisplatin,NA,NA,1,9.9 months,1.6 months,0.84 (0.74-0.96),NA,NA,1,NA,NA,NA,NA,Deteriorated toxicity profile,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Erlotinib,-,Placebo,Stage III or IV disease maintenance after responding to 4-6 cycles platinum doublet,Thoracic Malignancies,Non-small-cell Lung Cancer,-,Metastatic,1,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70112-1/fulltext,NA,NA,Placebo,NA,NA,NA,NA,Form 2a,PFS,Stage III or IV disease maintenance after responding to 4-6 cycles platinum doublet,SATURN,            Metastatic    ,NA,Non-small-cell Lung Cancer,Thoracic Malignancies,NA,NA,0.71 (0.62-0.82),1,11 months,1 month ,0.81 (0.70-0.95),11.1 weeks,1.2 weeks,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Imiquimod 5% cream,-,Placebo,Superficial Basal Cell Carcinoma in adults with normal immune system when surgical methods are less appropriate,Skin Cancers,Non-melanoma skin cancer,-,Early,C,NA,NA,https://www.jaad.org/article/S0190-9622(03)04597-3/fulltext,NA,NA,Placebo,NA,NA,NA,C,Form 1,pCR (histologic clearance rates),Superficial Basal Cell Carcinoma in adults with normal immune system when surgical methods are less appropriate,NA,            Early    ,NA,Non-melanoma skin cancer,Skin Cancers,NA,3% vs 79% (5 days) -82% (7 days),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Ipilimumab,-,Placebo,Adjuvant stage III melanoma,Skin Cancers,Melanoma,-,Adjuvant,A,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1611299?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30015-3/fulltext,NA,Placebo,NA,NA,NA,A,Form 1,5-years DFS,Adjuvant stage III melanoma,EORTC 18071,            Adjuvant    ,NA,Melanoma,Skin Cancers,NA,NA,NA,NA,54.40 %,11 %,0.76 (0.64-0.89),NA,NA,NA,NA,No QoL benefit,22.07.2020,NA,NA,NA,DFS,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Nivolumab,Ipilimumab,Ipilimumab,1st line advanced or metastatic melanoma,Skin Cancers,Melanoma,-,Advanced,4,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1709684?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub3dwww.ncbi.nlm.nih.gov,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30700-9/fulltext,https://www.nejm.org/doi/full/10.1056/NEJMoa1910836,Ipilimumab,NA,NA,NA,NA,Form 2a,PFS and OS ,1st line advanced or metastatic melanoma,CheckMate 067,            Advanced    ,NA,Melanoma,Skin Cancers,Ipilimumab,NA,0.42 (0.35-0.51),4,19.9 months  - 5-years 26%,18.4 months*  - 5-years 26% (with plateau),0.52 (0.42-0.64),2.9 months,8.6 months,4,NA,No QoL benefit,21.07.2020,NA,Higher toxicity and discontinuation rate,NA,OS,https://www.ejcancer.com/article/S0959-8049(17)30995-4/fulltext,*Calculated estimate of gain based on PE HR 0.52,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Nivolumab,-,Ipilimumab,1st line advanced or metastatic melanoma,Skin Cancers,Melanoma,-,Advanced,4,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1709684?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub3dwww.ncbi.nlm.nih.gov,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30700-9/fulltext,https://www.nejm.org/doi/full/10.1056/NEJMoa1910836,Ipilimumab,NA,NA,NA,NA,Form 2a,PFS and OS ,1st line advanced or metastatic melanoma,CheckMate 067,            Advanced    ,NA,Melanoma,Skin Cancers,NA,NA,0.53 (0.44-0.64),4,19.9 months  - 5-years 26%,17.0 months -  5-years 18% (with plateau),0.63 (0.52-0.76),2.9 months,4 months,4,NA,No QoL benefit,22.07.2020,NA,NA,NA,OS,https://www.ejcancer.com/article/S0959-8049(17)30995-4/fulltext,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Ipilimumab,Glycoprotein 100 (GP100),Glycoprotein 100 (GP100),Previously treated metastatic,Skin Cancers,Melanoma,HLA-A*0201,Metastatic,4,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1003466?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA,Glycoprotein 100 (GP100),NA,NA,NA,NA,Form 2a,OS,Previously treated metastatic,NA,            Metastatic    ,HLA-A*0201,Melanoma,Skin Cancers,Glycoprotein 100 (GP100),NA,NA,4,6.4 months,3.6 months,0.68 (0.55-0.85),NA,NA,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Ipilimumab,-,Glycoprotein 100 (GP100),Previously treated metastatic,Skin Cancers,Melanoma,HLA-A*0201,Metastatic,4,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1003466?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA,Glycoprotein 100 (GP100),NA,NA,NA,NA,Form 2a,OS,Previously treated metastatic,NA,            Metastatic    ,HLA-A*0201,Melanoma,Skin Cancers,NA,NA,NA,4,6.4 months,3.7 months,0.66 (0.51-0.87),NA,NA,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Vemurafenib,-,Dacarbazine,1st line or 2nd line after interleukin-2 metastatic melanoma with BRAF V600E and V600K mutations,Skin Cancers,Melanoma,BRAF+,Metastatic,4,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1103782?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70012-9/fulltext,NA,Dacarbazine,NA,NA,NA,NA,Form 2a,PFS and OS              V600E,1st line or 2nd line after interleukin-2 metastatic melanoma with BRAF V600E and V600K mutations,BRIM-3,            Metastatic    ,BRAF+,Melanoma,Skin Cancers,NA,NA,0.39 (0.33-0.47),4,10 months,3.3 months,0.75 (0.60-0.93),1.6 months,5.3 months,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Vemurafenib,-,Dacarbazine,1st line or 2nd line after interleukin-2 metastatic melanoma with BRAF V600E and V600K mutations,Skin Cancers,Melanoma,BRAF+,Metastatic,4,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1103782?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70012-9/fulltext,NA,Dacarbazine,NA,NA,NA,NA,Form 2a,PFS and OS               V600K,1st line or 2nd line after interleukin-2 metastatic melanoma with BRAF V600E and V600K mutations,BRIM-3,            Metastatic    ,BRAF+,Melanoma,Skin Cancers,NA,NA,0.30 (0.16-0.56),4,7.6 months,6.9 months,0.43 (0.21-0.90),1.7 months,4.2 months,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Trametinib,-,Dacarbazine or paclitaxel,Unresectable or metastatic melanoma with BRAF V600E/K mutation,Skin Cancers,Melanoma,BRAF+,Metastatic,4,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1203421?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov,https://www.annalsofoncology.org/article/S0923-7534(19)34272-3/fulltext,https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.643,Dacarbazine or paclitaxel ,NA,NA,NA,NA,Form 2b,PFS (crossover allowed),Unresectable or metastatic melanoma with BRAF V600E/K mutation,METRIC,            Metastatic    ,BRAF+,Melanoma,Skin Cancers,NA,NA,0.45 (0.33-0.63),4,NA,NA,Not significant ,1.5 months,3.3 months,3,1+,Improved,23.07.2020,NA,NA,NA,PFS,https://www.ejcancer.com/article/S0959-8049(18)31561-2/fulltext,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Trametinib,Dabrafenib,Dabrafenib,1st line unresectable or metastatic melanoma with the BRAF V600E mutation,Skin Cancers,Melanoma,BRAF+,Metastatic,4,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1210093?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA,Dabrafenib,NA,NA,NA,NA,Form 2b,PFS,1st line unresectable or metastatic melanoma with the BRAF V600E mutation,NA,            Metastatic    ,BRAF+,Melanoma,Skin Cancers,Dabrafenib,NA,0.39 (0.25-0.62),4,NA,NA,NA,5.8 months,3.6 months,3,1+,12% reduction skin cancer,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Dabrafenib,-,Dacarbazine,1st line unresectable or metastatic melanoma with the BRAF V600E mutation,Skin Cancers,Melanoma,BRAF+,Metastatic,4,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60868-X/fulltext,https://academic.oup.com/annonc/article/25/7/1428/2801216,NA,Dacarbazine,NA,NA,NA,NA,Form 2b,PFS (crossover allowed),1st line unresectable or metastatic melanoma with the BRAF V600E mutation,BREAK-3,            Metastatic    ,BRAF+,Melanoma,Skin Cancers,NA,NA,0.35 (0.20-0.61),4,NA,NA,NA,2.9 months,3.8 months,3,1+,Improved,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Trametinib,Dabrafenib,Vemurafenib,1st line unresectable or metastatic melanoma with the BRAF V600E mutation,Skin Cancers,Melanoma,BRAF+,Metastatic,5,NA,NA,https://www.nejm.org/doi/full/10.1056/nejmoa1412690,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00087-X/fulltext,https://www.nejm.org/doi/full/10.1056/NEJMoa1904059,Vemurafenib ,NA,NA,NA,NA,Form 2a,OS,1st line unresectable or metastatic melanoma with the BRAF V600E mutation,COMBI-v,            Metastatic    ,BRAF+,Melanoma,Skin Cancers,Dabrafenib,NA,0.56 (0.46-0.69),5,18.0 months*    3-years survival 31%,8.0 months *      3-years survival 13%,0.69 (0.53-0.89) Interim OS (p=0.005<0.02),7.3 months,4.1 months,4,NA,17% reduction skin cancer,23.07.2020,1+,Improved QoL (exploratory outcome) **,NA,OS,NA,* Estimated from Kaplan-Meier plot. ** QoL evaluated as an exploratory endpoint  (as distinct from primary or secondary endpoint) is not eligible for ESMO-MCBS grading.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Cobimetinib,Vemurafenib,Vemurafenib + placebo,1st line unresectable or metastatic melanoma with the BRAF V600E mutation,Skin Cancers,Melanoma,BRAF+,Metastatic,4,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30122-X/fulltext,https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-017-1246-0,https://www.annalsofoncology.org/article/S0923-7534(19)32016-2/abstract,Vemurafenib + placebo,NA,NA,NA,NA,Form 2a,PFS,1st line unresectable or metastatic melanoma with the BRAF V600E mutation,coBRIM,            Metastatic    ,BRAF+,Melanoma,Skin Cancers,Vemurafenib,NA,0.58 (0.46-0.72),4,17.4 months,4.9 months,0.70 (0.55-0.90),7.2 months,5.1 months,3,1+,9% reduction skin cancer,22.07.2020,NA,2.8% increase Grade 3+ retinopathy,NA,OS,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Nivolumab,-,Dacarbazine,1st line unresectable or metastatic BRAF-V600-WT,Skin Cancers,Melanoma,-,Metastatic,4,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1412082?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA,Dacarbazine,NA,NA,NA,NA,Form 2a,OS,1st line unresectable or metastatic BRAF-V600-WT,CheckMate 066,            Metastatic    ,NA,Melanoma,Skin Cancers,NA,NA,0.43 (0.34-0.56),4,10.8 months,6+ months,0.42 (0.25-0.73),2.2 months,2.9 months,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Ipilimumab,Dacarbazine,Dacarbazine + placebo,1st line metastatic,Skin Cancers,Melanoma,-,Metastatic,4,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1104621?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,https://                                    http://ascopubs.org/doi/abs/10.1200/JCO.2014.56.6018?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,NA,Dacarbazine + placebo,NA,NA,NA,A,Form 1/Form 2a,OS ,1st line metastatic,CA184-024,            Metastatic    ,NA,Melanoma,Skin Cancers,Dacarbazine,NA,NA,4,11.2 months       ,2.1 months                                               11.1% at 2 years                 9.4% at 5 years,0.69 (0.57-0.84),NA,NA,4,NA,NA,NA,NA,NA,Yes ,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Pembrolizumab,-,Investigator-choice chemotherapy (Randomised phase II study),2nd line metastatic after failure of ipilimumab BRAF or MEK inhibitor,Skin Cancers,Melanoma,-,Metastatic,3,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00083-2/fulltext,NA,NA,Investigator-choice chemotherapy (Randomised phase II study),NA,NA,NA,NA,Form 2b,PFS       2 mg/kg,2nd line metastatic after failure of ipilimumab BRAF or MEK inhibitor,KEYNOTE-002,            Metastatic    ,NA,Melanoma,Skin Cancers,NA,NA,0.57 (0.45-0.73) plateau PFS gain >10% at 1 year,3,NA,NA,NA,2.7 months,0.2 months ,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,1+,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Pembrolizumab,-,Investigator-choice chemotherapy (Randomised phase II study),2nd line metastatic after failure of ipilumumab BRAF or MEK inhibitor,Skin Cancers,Melanoma,BRAF+,Metastatic,3,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00083-2/fulltext,NA,NA,Investigator-choice chemotherapy (Randomised phase II study),NA,NA,NA,NA,Form 2b,PFS    10 mg/kg,2nd line metastatic after failure of ipilumumab BRAF or MEK inhibitor,KEYNOTE-002,            Metastatic    ,BRAF+,Melanoma,Skin Cancers,NA,NA,0.50 (0.39-0.64) plateau with >10% gain at 1 year,3,NA,NA,NA,2.7 months,0.2 months ,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,1+,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Everolimus,-,Placebo,"Progressive, well differentiated, non-functional neuroendocrine tumours of gastrointestinal or lung origin with unresectable, locally advanced or metastatic disease",Endocrine Tumours,Neuroendocrine Tumour,Gastrointestinal or lung,Metastatic,3,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)00817-X/fulltext,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30471-0/fulltext,NA,Placebo,NA,NA,NA,NA,Form 2b,PFS,"Progressive, well differentiated, non-functional neuroendocrine tumours of gastrointestinal or lung origin with unresectable, locally advanced or metastatic disease",RADIANT 4 ,            Metastatic    ,Gastrointestinal or lung ,Neuroendocrine Tumour,Endocrine Tumours,NA,NA,0.48 (0.35-0.67),3,NA,2.4 months (not statistically significant),Not statistically significant ,3.9 months,7.1 months,3,NA,No benefit,20.04.2020,NA,Moderate toxicity,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Vandetanib,-,Placebo,Unresectable locally advanced or metastatic hereditary or sporadic medullary thyroid cancer 1st or 2nd line,Endocrine Tumours,Thyroid Cancer,Medullary,Metastatic,3,NA,NA,http://ascopubs.org/doi/abs/10.1200/JCO.2011.35.5040?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,NA,NA,Placebo,NA,NA,NA,NA,Form 2b,PFS,Unresectable locally advanced or metastatic hereditary or sporadic medullary thyroid cancer 1st or 2nd line ,NA,            Metastatic    ,Medullary,Thyroid Cancer,Endocrine Tumours,NA,NA,0.46 (0.31-0.69),3,NA,NA,NA,19.3 months,11.2 months,3,NA,NA,NA,NA,Deteriorated toxicity profile. Patients receiving vandetanib experienced a statistically significant delay in time to worsening of pain compared with those receiving placebo        ,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Cabozantinib,-,Placebo,"Progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma 1st or 2nd line",Endocrine Tumours,Thyroid Cancer,"TKI targeting RET, MET, VEGFR2",Metastatic,3,NA,NA,http://ascopubs.org/doi/abs/10.1200/JCO.2012.48.4659?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,NA,NA,Placebo,NA,NA,NA,NA,Form 2b,PFS,"Progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma 1st or 2nd line",NA,            Metastatic    ,"TKI targeting RET, MET, VEGFR2",Thyroid Cancer,Endocrine Tumours,NA,NA,0.28 (0.19-0.40),3,NA,NA,Interim analysis NS,4 months,7.2 months,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Dinutuximab,Cis retinoic acid+GMCSF+IL2,Cis retinoic acid,<32 years old with high-risk neuroblastoma after remission and stem cell transplatation,Central Nervous System Malignancies,Neuro-oncology cancer,Neuroblastoma,Early,A,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa0911123?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,https://link.springer.com/article/10.1007%2Fs11523-016-0420-2,NA,Cis retinoic acid ,NA,NA,NA,A,Form 1,EFS,<32 years old with high-risk neuroblastoma after remission and stem cell transplatation,NA,            Early    ,Neuroblastoma,Neuro-oncology cancer,Central Nervous System Malignancies,Cis retinoic acid+GMCSF+IL2,NA,NA,NA,5-year survival 57%,Gain 17%,0.58 (0.37-0.91),2 years 45%,Gain 20%,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Radium-223,Best standard of care,Best standard of care + placebo,"Late line and bone pain, castration-refractory, late line and bone pain",Genitourinary Cancers,Prostate cancer,-,Metastatic,5,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1213755?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA,Best standard of care + placebo,NA,NA,NA,NA,Form 2a,OS,"Late line and bone pain, castration-refractory, late line and bone pain",ALSYMPCA,            Metastatic    ,NA,Prostate cancer,Genitourinary Cancers,Best standard of care,NA,NA,5,11.3 months,3.6 months,0.70 (0.55-0.83),NA,NA,4,1+,Improved,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Abiraterone,Prednisone,Prednisone + placebo,2nd line castration-refractory after docetaxel,Genitourinary Cancers,Prostate cancer,-,Metastatic,4,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1014618?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA,Prednisone + placebo,NA,NA,NA,NA,Form 2a,OS,2nd line castration-refractory after docetaxel,COU-AA-301,            Metastatic    ,NA,Prostate cancer,Genitourinary Cancers,Prednisone,NA,NA,4,10.9 months,3.9 months,0.65 (0.54-0.77),NA,NA,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Enzalutamide,-,Placebo,2nd line castration-refractory after docetaxel,Genitourinary Cancers,Prostate cancer,-,Metastatic,4,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1207506?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA,Placebo,NA,NA,NA,NA,Form 2a,OS,2nd line castration-refractory after docetaxel,NA,            Metastatic    ,NA,Prostate cancer,Genitourinary Cancers,NA,NA,NA,4,13.6 months,4.8 months,0.63 (0.53-0.75),NA,NA,3,1+,Improved,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Enzalutamide,-,Placebo,Castraction-refractory pre-docetaxel (early termination with crossover),Genitourinary Cancers,Prostate cancer,-,Metastatic,4,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1405095?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA,Placebo,NA,NA,NA,NA,Form 2a,PFS and OS,Castraction-refractory pre-docetaxel (early termination with crossover),AFFIRM,            Metastatic    ,NA,Prostate cancer,Genitourinary Cancers,NA,NA,0.19 (0.15-0.23),4,30.2 months,2.2 months,0.71 (0.60-0.84),3.9 months,>12 months,3,1+,Delayed deterioration,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Docetaxel  Q3w,Prednisone,Mitoxantrone + prednisone,Castraction-refractory,Genitourinary Cancers,Prostate cancer,-,Metastatic,3,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa040720?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA,Mitoxantrone + prednisone,NA,NA,NA,NA,Form 2a,OS,Castraction-refractory,NA,            Metastatic    ,NA,Prostate cancer,Genitourinary Cancers,Prednisone,NA,NA,3,16.5 months,2.4 months,0.76 (0.62-0.94),NA,NA,2,1+,Improved,NA,NA,NA,NA,NA,NA,-,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Cabazitaxel,Prednisone,Mitoxantrone + prednisone,Castraction-refractory after docetaxel,Genitourinary Cancers,Prostate cancer,-,Metastatic,2,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61389-X/fulltext,NA,NA,Mitoxantrone + prednisone,NA,NA,NA,NA,Form 2a,OS,Castraction-refractory after docetaxel,TROPIC,            Metastatic    ,NA,Prostate cancer,Genitourinary Cancers,Prednisone,NA,NA,2,12.7 months,2.4 months,0.70 (0.59-0.83),NA,NA,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Nivolumab,-,Everolimus,2nd line RCC clear cell after TKI,Genitourinary Cancers,Renal cell cancer,-,Metastatic,5,NA,NA,https://www.nejm.org/doi/full/10.1056/NEJMoa1510665,NA,NA,Everolimus,NA,NA,NA,NA,Form 2a,OS, 2nd line RCC clear cell after TKI,CheckMate 025,            Metastatic    ,NA,Renal cell cancer,Genitourinary Cancers,NA,NA,NA,5,19.6 months,5.4 months,0.73 (0.57-0.93),NA,NA,4,NA,NA,NA,1+,Reduced grade 3/4 adverse events 19% vs 37%,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Axitinib,-,Sorafenib,2nd line in advanced renal cell carcinoma,Genitourinary Cancers,Renal cell cancer,-,Metastatic,4,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61613-9/abstract?rss=yes&code=lancet-site,NA,NA,Sorafenib,NA,NA,NA,NA,Form 2b,PFS,2nd line in advanced renal cell carcinoma,AXIS,            Metastatic    ,NA,Renal cell cancer,Genitourinary Cancers,NA,NA,0.67 (0.54-0.81),4,NA,NA,NA,4.7 months,2.0 months,3,NA,NA,NA,1+,Reduced,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Pazopanib,-,Sunitinib,1st line metastatic RCC with clear cell component,Genitourinary Cancers,Renal cell cancer,-,Metastatic,4,NA,NA,https://www.nejm.org/doi/full/10.1056/NEJMoa1303989,NA,NA,Sunitinib,NA,NA,NA,NA,Form 2c,PFS non-inferiority,1st line metastatic RCC with clear cell component, COMPARZ,            Metastatic    ,NA,Renal cell cancer,Genitourinary Cancers,NA,NA,NS,4,NA,NA,NA,9.5 months,NA,4,NA,NA,NA,NA,Reduced,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Sunitinib,-,Interferon,1st line metastatic RCC,Genitourinary Cancers,Renal cell cancer,-,Metastatic,4,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa065044?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,http://ascopubs.org/doi/abs/10.1200/JCO.2008.20.1293?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,NA,Interferon,NA,NA,NA,NA,Form 2b,PFS crossover allowed,1st line metastatic RCC,NA,            Metastatic    ,NA,Renal cell cancer,Genitourinary Cancers,NA,NA,0.42 (0.32-0.54),4,21.8 months,4.6 months,0.82 (0.67-1.00) (cross-over allowed)                                                  NS,5 months,6 months,3,1+,Improved,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Sorafenib,-,Placebo,2nd line locally advanced or metastatic RCC (Randomised phase II study),Genitourinary Cancers,Renal cell cancer,-,Metastatic,3,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa060655?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA,Placebo,NA,NA,NA,NA,Form 2a,OS,2nd line locally advanced or metastatic RCC (Randomised phase II study),TARGET,            Metastatic    ,NA,Renal cell cancer,Genitourinary Cancers,NA,NA,0.44 (0.35-0.55),3,15.9 months,3.4 months,0.77 (0.63-0.95),2.8 months,2.7 months,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Everolimus,-,Placebo,2nd or 3rd line after TKI metastatic RCC,Genitourinary Cancers,Renal cell cancer,-,Metastatic,3,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61039-9/fulltext,https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.25219,NA,Placebo,NA,NA,NA,NA,Form 2b,PFS crossover allowed,2nd or 3rd line after TKI metastatic RCC,RECORD-1,            Metastatic    ,NA,Renal cell cancer,Genitourinary Cancers,NA,NA,0.33 (0.25-0.43) ,3,NS (Cross-over 80%),NA,NA,1.9 months,3 months ,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Pazopanib,-,Placebo,2nd line locally advanced or metastatic RCC,Genitourinary Cancers,Renal cell cancer,-,Metastatic,3,NA,NA,http://ascopubs.org/doi/abs/10.1200/JCO.2009.23.9764?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,NA,NA,Placebo,NA,NA,NA,NA,Form 2b,PFS crossover allowed,2nd line locally advanced or metastatic RCC,NA,            Metastatic    ,NA,Renal cell cancer,Genitourinary Cancers,NA,NA,0.46 (0.34-0.62),3,NA,NA,NA,4.2 months,5 months,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Bevacizumab,Interferon,Interferon + placebo,1st line metastatic RCC with clear cell,Genitourinary Cancers,Renal cell cancer,-,Metastatic,3,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(07)61904-7/fulltext,NA,NA,Interferon + placebo,NA,NA,NA,NA,Form 2b,OS  and PFS,1st line metastatic RCC with clear cell,AVOREN,            Metastatic    ,NA,Renal cell cancer,Genitourinary Cancers,Interferon,NA,0.63 (0.52-0.75),3,NA,NA,NS,5.4 months,4.8 months,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Cabozantinib,-,Everolimus,2nd line clear cell RCC after progression on TKI,Genitourinary Cancers,Renal cell cancer,-,Metastatic,3,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30107-3/fulltext,https://www.nejm.org/doi/10.1056/NEJMoa1510016?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,Everolimus,NA,NA,NA,NA,Form 2a,PFS,2nd line clear cell RCC after progression on TKI,METEOR,            Metastatic    ,NA,Renal cell cancer,Genitourinary Cancers,NA,NA,0.58 (0.45-0.75),3,16.5 months,4.9 months,0.66 (0.53-0.83),3.8 months,3.6 months,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Lenvatinib,Everolimus,Everolimus (Randomised phase II study),2nd line clear cell RCC after progression on TKI,Genitourinary Cancers,Renal cell cancer,-,Metastatic,4,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00290-9/fulltext,NA,NA, Everolimus (Randomised phase II study),NA,NA,NA,NA,Form 2a,PFS - Combined,2nd line clear cell RCC after progression on TKI,NA,            Metastatic    ,NA,Renal cell cancer,Genitourinary Cancers,Everolimus ,NA,0.40 (0.24-0.68),4,15.4 months,10.1+ months,0.51 (0.30-0.88) ,5.5 months,9.1 months,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Lenvatinib,-,Everolimus (Randomised phase II study),2nd line clear cell RCC after progression on TKI,Genitourinary Cancers,Renal cell cancer,-,Metastatic,3,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00290-9/fulltext,NA,NA,Everolimus (Randomised phase II study),NA,NA,NA,NA,Form 2b,PFS,2nd line clear cell RCC after progression on TKI,NA,            Metastatic    ,NA,Renal cell cancer,Genitourinary Cancers,NA,NA,0.61 (0.38-0.98),3,15.4 months,3.7 months,0.68 (0.41-1.14) NS,5.5 months,1.9 months,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Lenvatinib,-,Sorafenib,1st line advanced or unresectable HCC,Gastrointestinal Cancers,Hepatobiliary Cancers,Hepatocellular Carcinoma,Locally advanced,4,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30207-1/fulltext,NA,NA,Sorafenib,NA,NA,NA,NA,Form 2c,"OS non-inferiority, inferiority margin: 1.08",1st line advanced or unresectable HCC,REFLECT,            Locally advanced    ,Hepatocellular Carcinoma,Hepatobiliary Cancers,Gastrointestinal Cancers,NA,NA,0.66 (0.57-0.77),4,12.3 months,1.3 months,0.92 (0.79 - 1.06),3.7 months,3.7 months,4,NA,Delayed deterioration,NA,NA,NS,NA,NA,NA,NA,NA,"QoL declined in both groups after treatment, a clinically meaningful delay in deterioration for multiple domains was observed in lenvatinib compared with sorafenib",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Cabozantinib,-,Placebo,2nd line Unresectable HCC after TKI,Gastrointestinal Cancers,Hepatobiliary Cancers,Hepatocellular Carcinoma,Locally advanced,3,NA,NA,https://www.nejm.org/doi/full/10.1056/NEJMoa1717002,NA,NA,Placebo,NA,NA,NA,NA,Form 2a,OS,2nd line Unresectable HCC after TKI,CELESTIAL,            Locally advanced    ,Hepatocellular Carcinoma,Hepatobiliary Cancers,Gastrointestinal Cancers,NA,NA,0.44 (0.36-0.52),3,8.0 months,2.2 months,0.76 (0.63 - 0.92),1.9 months,3.3 months,3,NA,NA,NA,NA,Increased,NA,NA,NA,NA,NA,NA,14.01.2019,NA,NA,NA,NA,NA,NA,NA,NA,NA
Regorafenib,-,Placebo,2nd line Unresectable HCC after TKI,Gastrointestinal Cancers,Hepatobiliary Cancers,Hepatocellular Carcinoma,Locally advanced,4,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32453-9/fulltext,NA,NA,Placebo,NA,NA,NA,NA,Form 2a,OS,2nd line Unresectable HCC after TKI,RESORCE,            Locally advanced    ,Hepatocellular Carcinoma,Hepatobiliary Cancers,Gastrointestinal Cancers,NA,NA,0.46 (0.37-0.56),4,7.8 months,2.8 months - 2-year survival gain >10% ,0.63 (0.50 - 0.79),1.5 months,1.6 months,4,NA,NA,NA,NA,Increased,NA,NA,NA,NA,NA,NA,14.01.2019,NA,NA,NA,NA,NA,NA,NA,NA,NA
Tivozanib,-,Sorafenib,"Recurrent or metastatic RCC with clear cell component, and prior nephrectomy",Genitourinary Cancers,Renal cell cancer,-,Metastatic,1,NA,NA,http://ascopubs.org/doi/full/10.1200/JCO.2012.47.4940?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,NA,NA,Sorafenib,NA,NA,NA,NA,Form 2b,PFS,"Recurrent or metastatic RCC with clear cell component, and prior nephrectomy",NA,            Metastatic    ,NA,Renal cell cancer,Genitourinary Cancers,NA,NA,0.80 (0.64-0.99),1,OS (Not significant),NA,NA,9.1 months,2.8 months,2,-1,No QoL benefit,NA,NA,NA,NA,NA,NA,NA,NA,NA,21.02.19,NA,NA,NA,NA,NA,NA,NA,NA,NA
"FLOT (docetaxel, oxaliplatin, fluorouracil and leucovorin)",-,Fluorouracil or capecitabine plus cisplatin and epirubicin,"Resectable gastric or gastro-oesophageal junction adenocarcinoma with clinical stage cT2 or higher, nodal positive (cN+) disease or both",Gastrointestinal Cancers,Gastric and gastro-oesophageal junction cancers,-,Early,A,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30531-9/fulltext,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32557-1/fulltext,NA,Fluorouracil or capecitabine plus cisplatin and epirubicin ,NA,NA,NA,A,Form 1,OS (Phase II/III),"Resectable gastric or gastro-oesophageal junction adenocarcinoma with clinical stage cT2 or higher, nodal positive (cN+) disease or both",FLOT4,            Early    ,NA,Gastric and gastro-oesophageal junction cancers ,Gastrointestinal Cancers,NA,NA,NA,NA,35 months (median)  OS at 3 years: 48%,15 months (median)  OS at 3 years: 9%,0.77 (0.63–0.94),NA,NA,NA,NA,QoL not available,NA,NA,AEs similar ,NA,NA,NA,NA,NA,NA,03.05.2019,NA,NA,NA,NA,NA,NA,NA,NA,NA
Gemcitabine,Capecitabine,Gemcitabine,Resected pancreatic ductal adenocarcinoma,Gastrointestinal Cancers,Pancreatic cancer,-,Early,A,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32409-6/fulltext,NA,NA,Gemcitabine,NA,NA,NA,A,Form 1,OS,Resected pancreatic ductal adenocarcinoma,ESPAC-4,            Early    ,NA,Pancreatic cancer,Gastrointestinal Cancers,Capecitabine,NA,NA,NA,25.5 months,2.5 months >10% at five years,0.82 (0.68-0.98),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,15.05.2019,NA,NA,NA,NA,NA,NA,NA,NA,NA
mFOLFIRINOX,-,Gemcitabine,Resected pancreatic ductal adenocarcinoma,Gastrointestinal Cancers,Pancreatic cancer,-,Early,A,NA,NA,https://www.nejm.org/doi/full/10.1056/NEJMoa1809775?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,https://www.nejm.org/doi/10.1056/NEJMoa1011923?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,Gemcitabine,NA,NA,NA,A,Form 1,OS,Resected pancreatic ductal adenocarcinoma,PRODIGE 24/CCTG PA. 6 trial,            Early    ,NA,Pancreatic cancer,Gastrointestinal Cancers,NA,NA,NA,NA,35.0 months,19.4 months 3-year survival gain 14.8%,0.64 (0.48-0.86),NA,NA,NA,NA,NA,NA,NA,Increased acute toxicity,NA,NA,NA,NA,NA,NA,14.05.2019,NA,NA,NA,NA,NA,NA,NA,NA,NA
Nanoliposomal irinotecan,5-FU/LV,5-fluorouracil and folinic acid,Pancreatic adenocarcinoma previously treated with gemcitabine-based therapy,Gastrointestinal Cancers,Pancreatic cancer,-,Metastatic,2,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)00986-1/fulltext,NA,NA,5-fluorouracil and folinic acid,NA,NA,NA,NA,Form 2a,OS,Pancreatic adenocarcinoma previously treated with gemcitabine-based therapy,NAPOLI-1,            Metastatic    ,NA,Pancreatic cancer,Gastrointestinal Cancers,5-FU/LV,NA,NA,2,4.2 months,1.9 months,0.67 (0.49-0.92),NA,NA,2,NA,Similar QoL ,NA,NA,More frequent grade 3-4 adverse events,NA,NA,NA,NA,NA,NA,14.05.2019,NA,NA,NA,NA,NA,NA,NA,NA,NA
Osimertinib,-,Gefitinib or erlotinib,Previously untreated EGFR mutated (exon 19 deletion or L858R),Thoracic Malignancies,Non-small-cell Lung Cancer,EGFR+ (exon 19 deletion or L858R),Advanced,4,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1713137,https://www.nejm.org/doi/full/10.1056/NEJMoa1913662?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,https://www.ejcancer.com/article/S0959-8049(19)30814-7/fulltext,Gefitinib or erlotinib,NA,NA,NA,NA,Form 2a,PFS,Previously untreated EGFR mutated (exon 19 deletion or L858R),FLAURA,            Advanced    ,EGFR+ (exon 19 deletion or L858R),Non-small-cell Lung Cancer,Thoracic Malignancies,NA,NA,0.46 (0.37-0.57),4,31.8 months,6.8 months,0.80 (0.64-1.00),10.2 months,8.7 months,3,NA,Similar between arms,30.04.2020,1+,Improved toxicity profile,NA,NA,NA,NA,NA,NA,15.05.2019,NA,NA,NA,NA,NA,NA,NA,NA,NA
Alectinib,-,Crizotinib,Untreated ALK-positive,Thoracic Malignancies,Non-small-cell Lung Cancer,ALK+,Metastatic,4,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)30565-2/fulltext,NA,NA,Crizotinib,NA,NA,NA,NA,Form 2b,PFS (independent review committee-assessed),Untreated ALK-positive ,J-ALEX,            Metastatic    ,ALK+,Non-small-cell Lung Cancer,Thoracic Malignancies,NA,NA,0.50 (0.36-0.70),4,NA,NA,NA,10.4 months,15.3 months,3,NA,NA,NA,1+,Improved toxicity profile,NA,NA,NA,NA,NA,NA,15.05.2019,NA,NA,NA,NA,NA,NA,NA,NA,NA
Alectinib,-,Chemotherapy (pemetrexed or docetaxel),Previously treated ALK-positive,Thoracic Malignancies,Non-small-cell Lung Cancer,ALK+,Metastatic,4,NA,NA,https://academic.oup.com/annonc/article/29/6/1409/4970555,NA,NA,Chemotherapy (pemetrexed or docetaxel),NA,NA,NA,NA,Form 2b,PFS (investigator assessment),Previously treated ALK-positive,ALUR,            Metastatic    ,ALK+,Non-small-cell Lung Cancer,Thoracic Malignancies,NA,NA,0.15 (0.08-0.29),4,NA,NA,NA,1.4 months,8.2 months,3,NA,NA,NA,1+,Improved toxicity profile,NA,NA,NA,NA,NA,NA,15.05.2019,NA,NA,NA,NA,NA,NA,NA,NA,NA
Atezolizumab,-,Docetaxel,Squamous or non-squamous stage IIIB or IV patients who had previously received one or two chemotherapy regimes,Thoracic Malignancies,Squamous or non-squamous non-small-cell lung cancer,-,Metastatic,5,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32517-X/fulltext,https://www.jto.org/article/S1556-0864(18)30611-7/fulltext,NA,Docetaxel,NA,NA,NA,NA,Form 2a,OS,Squamous or non-squamous stage IIIB or IV patients who had previously received one or two chemotherapy regimes,OAK,            Metastatic    ,NA,Squamous or non-squamous non-small-cell lung cancer,Thoracic Malignancies,NA,NA,NA,5,9.6 months,4.2 months,0.73 (0.62-0.87),NA,NA,4,NA,NA,16.03.2020,1+,Improved toxicity profile,NA,NA,NA,NA,NA,NA,15.05.2019,NA,NA,NA,NA,NA,NA,NA,NA,NA
Ceritinib,-,Chemotherapy (pemetrexed or docetaxel),Previously treated with chemotherapy and crizotinib ALK-positive stage IIIB or IV,Thoracic Malignancies,Non-small-cell Lung Cancer,ALK+,Metastatic,4,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30339-X/fulltext,NA,NA,Chemotherapy (pemetrexed or docetaxel),NA,NA,NA,NA,Form 2b,PFS,Previously treated with chemotherapy and crizotinib ALK-positive stage IIIB or IV ,ASCEND-5,            Metastatic    ,ALK+,Non-small-cell Lung Cancer,Thoracic Malignancies,NA,NA,0.49 (0.36-0.67),4,NA,NA,NA,1.6 months,3.8 months,3,1+,Improved overall health-related QoL,NA,NA,NA,NA,NA,NA,NA,NA,NA,15.05.2019,NA,NA,NA,NA,NA,NA,NA,NA,NA
Ceritinib,-,Chemotherapy,1st line ALK positive,Thoracic Malignancies,Non-small-cell Lung Cancer,ALK+,Metastatic,4,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)30123-X/fulltext,NA,NA,Chemotherapy,NA,NA,NA,NA,Form 2b,PFS,1st line ALK positive,ASCEND-4,            Metastatic    ,ALK+,Non-small-cell Lung Cancer,Thoracic Malignancies,NA,NA,0.55 (0.42-0.73),4,NA,NA,NA,8.1 months,8.5 months,3,1+,Delayed deterioration in overall health-related QoL,NA,NA,NA,NA,NA,NA,NA,NA,NA,15.05.2019,NA,NA,NA,NA,NA,NA,NA,NA,NA
Crizotinib,-,Single arm study,Cohort study 50 patients (86% had received at least one previous line of standard therapy),Thoracic Malignancies,Non-small-cell Lung Cancer,ROS1+,Advanced,3,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1406766?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,NA,NA,Single arm study,NA,NA,NA,NA,Form 3,ORR and mPFS (Phase I),Cohort study 50 patients (86% had received at least one previous line of standard therapy) ,NA,            Advanced    ,ROS1+,Non-small-cell Lung Cancer,Thoracic Malignancies,NA,NA,NA,3,NA,NA,NA,NA,NA,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,16.05.2019,"72% achieved in ORR (95% CI 58-84),  mPFS 19.2 months (95% CI 14.4 - not reached)",NA,NA,NA,NA,NA,NA,NA,NA
Dabrafenib,Trametinib,Single arm study,Cohort study 36 patients previously untreated,Thoracic Malignancies,Non-small-cell Lung Cancer,BRAF V600E - mutant,Advanced,2,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30679-4/fulltext,NA,NA,Single arm study,NA,NA,NA,NA,Form 3,ORR and mPFS (Phase II),Cohort study 36 patients previously untreated,NA,            Advanced    ,BRAF V600E - mutant,Non-small-cell Lung Cancer,Thoracic Malignancies,Trametinib,NA,NA,2,NA,NA,NA,NA,NA,3,NA,NA,NA,1-,Serious adverse events: 57%,NA,NA,NA,NA,NA,NA,16.05.2019,"64% achieved in ORR (95% CI 46-79),  mPFS 10.9 months (95% CI 7.0 - 16.6)",NA,NA,NA,NA,NA,NA,NA,NA
Dabrafenib,Trametinib,Single arm study,Cohort study 57 patients previously treated,Thoracic Malignancies,Non-small-cell Lung Cancer,BRAF V600E - mutant,Metastatic,2,NA,NA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993103/,NA,NA,Single arm study,NA,NA,NA,NA,Form 3,ORR and mPFS (Phase II),Cohort study 57 patients previously treated,NA,            Metastatic    ,BRAF V600E - mutant,Non-small-cell Lung Cancer,Thoracic Malignancies,Trametinib,NA,NA,2,NA,NA,NA,NA,NA,3,NA,NA,NA,1-,Serious adverse events: 56%,NA,NA,NA,NA,NA,NA,16.05.2019,"63.2% achieved in ORR (95% CI 49.3 - 75.6),  mPFS 9.7 months (95% CI 6.9 - 19.6)",NA,NA,NA,NA,NA,NA,NA,NA
Pembrolizumab,Chemotherapy (Pemetrexed),Chemotherapy,Previously untreated without EGFR or ALK mutations,Thoracic Malignancies,Non-small-cell Lung Cancer,-,Advanced,4,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1801005,https://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(19)30801-0.pdf,NA,Chemotherapy,NA,NA,NA,NA,Form 2a,PFS and OS (Crossover allowed),Previously untreated without EGFR or ALK mutations,KEYNOTE-189,            Advanced    ,NA,Non-small-cell Lung Cancer,Thoracic Malignancies,Chemotherapy (Pemetrexed),NA,0.52 (0.43-0.64),4,11.3 months,Above the cut-off of 3 months,0.49 (0.38-0.64),4.9 months,3.9 months,4,NA,Delayed deterioration (exploratory outcome not eligible for upgrade),30.04.2020,NA,Similar toxicity; discontinuation of treatment due to toxicity of pembrolizumab combination (13.3% vs 6.4%),NA,NA,NA,NA,NA,NA,17.05.2019,NA,NA,NA,NA,NA,NA,NA,NA,NA
Pertuzumab,Standard adjuvant chemotherapy + 1 year of treatment with trastuzumab,Placebo + standard adjuvant chemotherapy + 1 year of treatment with trastuzumab,Adjuvant early HER2+,Breast Cancer,Breast Cancer,HER2+,Early,B,NA,NA,https://www.nejm.org/doi/full/10.1056/nejmoa1703643,NA,NA,Placebo + standard adjuvant chemotherapy + 1 year of treatment with trastuzumab,NA,0.9% improvement in 3-year iDFS (94.1% vs 93.2%) in the ITT population ,iDFS 0.81 (0.66-1.00) in the ITT population,B,Form 1,iDFS,Adjuvant early HER2+ ,APHINITY,            Early    ,HER2+,Breast Cancer,Breast Cancer,Standard adjuvant chemotherapy + 1 year of treatment with trastuzumab,NA,NA,NA,Not yet reported,NA,NA,NA,NA,NA,NA,NA,NA,NA,Increased grade 3 diarrhoea (9.8% vs 3.7%),NA,NA,NA,NA,NA,NA,05.06.2019,NA,NA,NA,NA,NA,NA,NA,NA,NA
Neratinib,-,Placebo,After trastuzumab based adjuvant therapy in early HER2+,Breast Cancer,Breast Cancer,HER2+,Early,A,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30717-9/fulltext,NA,NA,Placebo,NA,2.5% improvement in 5-year iDFS (90.2% vs 87.7%) in the ITT population ,iDFS 0.73 (0.57-0.92) in the ITT population,A,From 1,iDFS,After trastuzumab based adjuvant therapy in early HER2+,ExteNET,            Early    ,HER2+,Breast Cancer,Breast Cancer,NA,NA,NA,NA,Not yet reported,NA,NA,NA,NA,NA,NA,NA,NA,NA,Increased grade ≥3 diarrhoea (40% vs 2%),NA,NA,NA,NA,NA,NA,05.06.2019,NA,NA,NA,NA,NA,NA,NA,NA,NA
Lenvatinib,-,Placebo,Progressive differentiated thyroid cancer that was refractory to radio-iodine-131,Endocrine Tumours,Thyroid Cancer,"MKI targeting VEGFR1, VEGFR2 and VEGFR3",-,3,NA,NA,https://www.nejm.org/doi/full/10.1056/NEJMoa1406470,NA,NA,Placebo,NA,NA,NA,NA,Form 2b,mPFS,Progressive differentiated thyroid cancer that was refractory to radio-iodine-131,SELECT,NA,"MKI targeting VEGFR1, VEGFR2 and VEGFR3",Thyroid Cancer,Endocrine Tumours,NA,NA,0.21 (0.16-0.28),3,"OS immature, not significant ",NA,NA,3.6 months,14.7 months,3,NA,NA,NA,NA,"Substantial toxicity was reported but this was not captured by the current ESMO-MCBS toxicity penalty criteria and, consequently, toxicity adjustment could not be applied",NA,NA,NA,NA,NA,NA,NA,NA,06.11.2019,NA,NA,NA,NA,NA,NA,NA
Sorafenib,-,Placebo,"Radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer",Endocrine Tumours,Thyroid Cancer,"MKI targeting VEGFR, PDGFR and Raf family kinases",-,2,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)60421-9/fulltext,NA,NA,Placebo,NA,NA,NA,NA,Form 2b,mPFS,"Radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer",DECISION,NA,"MKI targeting VEGFR, PDGFR and Raf family kinases",Thyroid Cancer,Endocrine Tumours,NA,NA,0.59 (0.45-0.76),2,"OS immature, not significant ",NA,NA,5.8 months,5.0 months,3,NA,NA,NA,-1,Increased toxicity,NA,NA,NA,NA,NA,NA,NA,NA,06.11.2019,NA,NA,NA,NA,NA,NA,NA
Vandetanib,-,Placebo,Unresectable locally advanced or metastatic hereditary or sporadic medullary thyroid cancer,Endocrine Tumours,Thyroid Cancer,"MKI targeting RET, VEGFR2 and EGFR",-,2,NA,NA,https://ascopubs.org/doi/full/10.1200/JCO.2011.35.5040?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed,NA,NA,Placebo,NA,NA,NA,NA,Form 2b,mPFS,Unresectable locally advanced or metastatic hereditary or sporadic medullary thyroid cancer,ZETA,NA,"MKI targeting RET, VEGFR2 and EGFR",Thyroid Cancer,Endocrine Tumours,NA,NA,0.46 (0.31-0.69),2,"OS immature, not significant ",NA,NA,19.3 months,11.2 months (reported estimate),3,NA,NA,NA,-1,Increased toxicity,NA,NA,NA,NA,NA,NA,NA,NA,06.11.2019,NA,NA,NA,NA,NA,NA,NA
Cabazitaxel,Prednisone or prednisolone,Abiraterone or enzalutamide (alternative to previously used),Metastatic castration-resistant prostate cancer after docetaxel and AST inhibitor,Genitourinary Cancers,Prostate cancer,-,-,3,NA,NA,https://www.nejm.org/doi/full/10.1056/NEJMoa1911206,NA,NA,Abiraterone or enzalutamide (alternative to previously used),NA,NA,NA,NA,Form 2a,PFS,Metastatic castration-resistant prostate cancer after docetaxel and AST inhibitor,CARD,NA,NA,Prostate cancer,Genitourinary Cancers,Prednisone or prednisolone,NA,0.54 (0.40-0.73),3,11.0 months,2.6 months,0.64 (0.46-0.89),3.7 months,4.3 months,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,02.12.2019,NA,02.12.2019,NA,NA,NA,NA,NA,NA,NA
Ramucirumab,-,Placebo,Advanced or cannot be removed by surgery with a high blood level of α fetoprotein (AFP) and previously treated with sorafenib,Gastrointestinal Cancers,Hepatobiliary Cancers,Hepatocellular Carcinoma,Advanced,1,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30937-9/fulltext,NA,NA,Placebo,NA,NA,NA,NA,Form 2a,OS,Advanced or cannot be removed by surgery with a high blood level of α fetoprotein (AFP) and previously treated with sorafenib ,REACH-2,            Advanced    ,Hepatocellular Carcinoma,Hepatobiliary Cancers,Gastrointestinal Cancers,NA,NA,NA,1,7.3 months,1.2 months, 0.71 (0.53 -0.95),NA,NA,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,04.12.2019,NA,04.12.2019,NA,NA,NA,NA,NA,NA,NA
Dacomitinib,-,Gefitinib,1st line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer,Thoracic Malignancies,Non-small-cell Lung Cancer,EGFR+,-,3,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30608-3/fulltext,https://ascopubs.org/doi/full/10.1200/JCO.2018.78.7994?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,NA,Gefitinib,NA,NA,NA,NA,Form 2a,PFS,1st line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer ,ARCHER 1050,NA,EGFR+,Non-small-cell Lung Cancer,Thoracic Malignancies,NA,NA,0.59 (0.47–0.74),3,26.8,7.3 months,0.76 (0.58–0.99),9.2 months,5.5 months,3,NA,No improvement,NA,NA,Increased toxicity,NA,NA,NA,NA,NA,NA,04.12.2019,NA,04.12.2019,NA,NA,NA,NA,NA,NA,NA
Lorlatinib,-,Single arm study,139 patients had received ≥1 generation ALK TKI (EXP3B to EXP5),Thoracic Malignancies,Non-small-cell Lung Cancer,ALK+,-,3,NA,NA,https://ascopubs.org/doi/full/10.1200/JCO.18.02236?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,NA,NA,Single arm study,NA,NA,NA,NA,Form 3,"ORR, DoR, PFS Phase I/II",139 patients had received ≥1 generation ALK TKI (EXP3B to EXP5) ,NA,NA,ALK+,Non-small-cell Lung Cancer,Thoracic Malignancies,NA,NA,NA,3,NA,NA,NA,NA,NA,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,04.12.2019,"40% achieved in ORR (95% CI 32%–49%), mPFS, 6.9 months (95% CI 5.4–8.2)",04.12.2019,7.1 months (95% CI 5.6–24.4) ,NA,NA,NA,NA,NA,NA
Larotrectinib,-,Single arm study,Refractory NTRK fusion–positive cancers,Refractory NTRK fusion–positive cancers,-,-,-,3,NA,NA,https://www.nejm.org/doi/full/10.1056/NEJMoa1714448,NA,NA,Single arm study,NA,NA,NA,NA,Form 3,RR,Refractory NTRK fusion–positive cancers,NA,NA,NA,NA,Refractory NTRK fusion–positive cancers,NA,NA,NA,3,NA,NA,NA,NA,NA,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,20.12.2019,NA,20.12.2019,9+ months,75% (independent review),NA,NA,NA,NA,NA
Olaparib,-,Placebo,"Maintenance therapy in newly diagnosed women with advanced high-grade cancer of the ovaries, fallopian tubes and peritoneum with BRCA mutations who have been treated with platinum-based chemotherapy and in whom this treatment has reduced or cleared the cancer",Gynaecological Malignancies,"Ovarian, fallopian tubes and peritoneum cancer",BRCA mutation,-,4,NA,NA,https://www.nejm.org/doi/full/10.1056/NEJMoa1810858,NA,NA,Placebo,NA,NA,NA,NA,From 2b,PFS,"Maintenance therapy in newly diagnosed women with advanced high-grade cancer of the ovaries, fallopian tubes and peritoneum with BRCA mutations who have been treated with platinum-based chemotherapy and in whom this treatment has reduced or cleared the cancer",SOLO-1,NA,BRCA mutation,"Ovarian, fallopian tubes and peritoneum cancer",Gynaecological Malignancies,NA,NA,0.30 (0.23-0.41)        ,4,NA,NA,NA,13.8 months,30+ months,3,NA,No significant benefit ,NA,NA,NA,NA,NA,NA,NA, >10% gain in PFS at 36 months,NA,10.01.2020,NA,10.01.2020,NA,NA,NA,NA,NA,NA,NA
Olaparib,-,Placebo,"Maintenance therapy in relapsed high-grade cancer of the ovaries, fallopian tubes and peritoneum with BRCA mutations after previous treatment and in whom platinum-based chemotherapy has reduced or cleared the cancer",Gynaecological Malignancies,"Ovarian, fallopian tubes and peritoneum cancer",BRCA mutation,-,4,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30469-2/fulltext,NA,NA,Placebo,NA,NA,NA,NA,Form 2b,PFS,"Maintenance therapy in relapsed high-grade cancer of the ovaries, fallopian tubes and peritoneum with BRCA mutations after previous treatment and in whom platinum-based chemotherapy has reduced or cleared the cancer",SOLO-2,NA,BRCA mutation,"Ovarian, fallopian tubes and peritoneum cancer",Gynaecological Malignancies,NA,NA,0.30 (0.22-0.41)           ,4,NA,NA,NA,5.5 months,13.6 months,3,NA,Not improved,NA,NA,NA,NA,NA,NA,NA, >10% gain in PFS at 12 months,NA,10.01.2020,NA,10.01.2020,NA,NA,NA,NA,NA,NA,NA
Trifluiridine/tipiracil (TAS-102),-,Placebo,Patients who have been treated with two prior lines of chemotherapy,Gastrointestinal Cancers,Gastric and gastro-oesophageal junction cancers,-,Metastatic,3,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30739-3/fulltext,NA,NA,Placebo,NA,NA,NA,NA,Form 2a,OS,Patients who have been treated with two prior lines of chemotherapy ,TAGS,            Metastatic    ,NA,Gastric and gastro-oesophageal junction cancers ,Gastrointestinal Cancers,NA,NA,NA,3,3.6 months,2.1 months,0.69 (0.56-0.85),NA,NA,3,NA,NA,NA,NA,NA,NA,OS,NA,NA,NA,NA,NA,NA,06.11.2019,NA,NA,NA,NA,NA,NA,NA
Pembrolizumab,Axitinib,Sunitinib,Previously untreated advanced renal cell carcinoma,Genitourinary Cancers,Renal cell cancer,-,Advanced,4,NA,NA,https://www.nejm.org/doi/full/10.1056/NEJMoa1816714,NA,NA,Sunitinib,NA,NA,NA,NA,Form 2b,PFS,Previously untreated advanced renal cell carcinoma ,KEYNOTE-426,            Advanced    ,NA,Renal cell cancer,Genitourinary Cancers,Axitinib,NA,0.69 (0.57-0.84),4,NA,NA,0.53 (0.38-0.74) (Interim analysis of survival met predefined threshold of P<0.0001 but OS not mature),11.1 months,4 months,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,12 months survival gain 12%,NA,17.02.2020,NA,17.02.2020,NA,NA,NA,NA,NA,NA,NA
Avelumab,Axitinib,Sunitinib,Previously untreated advanced renal cell carcinoma,Genitourinary Cancers,Renal cell cancer,-,Advanced,3,NA,NA,https://www.nejm.org/doi/full/10.1056/NEJMoa1816047,NA,NA,Sunitinib,NA,NA,NA,NA,Form 2b,PFS (ITT),Previously untreated advanced renal cell carcinoma ,JAVELIN Renal 101,            Advanced    ,NA,Renal cell cancer,Genitourinary Cancers,Axitinib,NA,0.69 (0.56-0.84),3,NA,NA,NA,8.4 months,5.4 months,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,17.02.2020,NA,17.02.2020,NA,NA,NA,NA,NA,NA,NA
Nivolumab,Ipilimumab,Sunitinib,1st line for intermediate and poor risk advanced metastatic renal cell carcinoma,Genitourinary Cancers,Renal cell cancer,-,Advanced metastatic,4,NA,NA,https://www.nejm.org/doi/full/10.1056/NEJMoa1712126,https://www.ncbi.nlm.nih.gov/pubmed/30658932,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30413-9/fulltext,Sunitinib,NA,NA,NA,NA,Form 2a,OS,1st line for intermediate and poor risk advanced metastatic renal cell carcinoma,CheckMate 214,            Advanced metastatic    ,NA,Renal cell cancer,Genitourinary Cancers,Ipilimumab,NA,NA,4,26.6 months,13 months (Calculated conservative estimate of gain based on PE HR 0.66),0.66 (0.54-0.80),NA,NA,4,NA,QoL benefit reported in exploratory evaluation not eligible for QoL adjustment,NA,NA,NA,NA,NA,NA,NA,NA,NA,17.02.2020,NA,17.02.2020,NA,NA,NA,NA,NA,NA,NA
Lanreotide,-,Placebo,Nonfunctioning entero-pancreatic neuroendocrine tumour grade 1 or 2 (Ki-67 values <10%) SSTR positive,Endocrine Tumours,Neuroendocrine Tumour,Entero-pancreatic,Metastatic,3,NA,NA,https://www.nejm.org/doi/full/10.1056/NEJMoa1316158,NA,NA,Placebo,NA,NA,NA,NA,Form 2b,PFS,Nonfunctioning entero-pancreatic neuroendocrine tumour grade 1 or 2 (Ki-67 values <10%) SSTR positive ,CLARINET,            Metastatic    ,Entero-pancreatic,Neuroendocrine Tumour,Endocrine Tumours,NA,NA,0.47 (0.30-0.73),3,"OS immature, not significant ",NA,NA,18.0 months,9.3+ months (Calculated estimate of gain based on point estimate HR 0.47),3,NA,QoL no benefit ,NA,NA,Low toxicity,NA,NA,NA,NA,PFS gain at 24 months: >10% (no plateau) ,NA,12.03.2020,NA,12.03.2020,NA,NA,NA,NA,NA,NA,NA
Everolimus,Best supportive care,Placebo,Progressive pancreatic neuroendocrine tumour grade 1 or 2 mostly non-functional,Endocrine Tumours,Neuroendocrine Tumour,Pancreatic,Advanced,3,NA,NA,https://www.nejm.org/doi/full/10.1056/nejmoa1009290,https://ascopubs.org/doi/full/10.1200/JCO.2016.68.0702?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,NA,Placebo,NA,NA,NA,NA,Form 2b,PFS ITT,Progressive pancreatic neuroendocrine tumour grade 1 or 2 mostly non-functional,RADIANT 3,            Advanced    ,Pancreatic ,Neuroendocrine Tumour,Endocrine Tumours,Best supportive care,NA,0.35 (0.27-0.45),3,37.7 months,6.3 months (not statistically significant),NS,4.6 months,6.4 months,3,NA,No QoL data,NA,NA,Moderate toxicity,NA,NA,NA,NA,NA,NA,12.03.2020,NA,12.03.2020,NA,NA,NA,NA,NA,NA,NA
Octreotide,-,Placebo,"Therapy-naive midgut neuroendocrine tumour, functional or non-functional",Endocrine Tumours,Neuroendocrine Tumour,Midgut,Metastatic,2,NA,NA,https://ascopubs.org/doi/10.1200/JCO.2009.22.8510,https://www.karger.com/Article/FullText/443612,NA,Placebo,NA,NA,NA,NA,Form 2b (Scoring of TTP on the same basis as PFS),TTP,"Therapy-naive midgut neuroendocrine tumour, functional or non-functional",PROMID,            Metastatic    ,Midgut,Neuroendocrine Tumour,Endocrine Tumours,NA,NA,0.34 (0.20-0.59),2,83.7 months,1.0 month (not significant),NS,6.0 months,8.3 months,3,1-,NA,NA,NA,Low toxicity,NA,TTP,NA,NA,NA,NA,12.03.2020,NA,12.03.2020,NA,NA,QoL no benefit,NA,NA,NA,NA
Sunitinib,-,Placebo,Progressive pancreatic neuroendocrine tumour,Endocrine Tumours,Neuroendocrine Tumour,Pancreatic,Advanced,3,NA,NA,https://www.nejm.org/doi/full/10.1056/nejmoa1003825,https://www.annalsofoncology.org/article/S0923-7534(19)32208-2/fulltext,NA,Placebo,NA,NA,NA,NA,Form 2b,PFS (crossover allowed),Progressive pancreatic neuroendocrine tumour,NA,            Advanced    ,Pancreatic ,Neuroendocrine Tumour,Endocrine Tumours,NA,NA,0.42 (0.26-0.66),3,29.1 months,9.5 months (not statistically significant),NS,5.5 months,5.9 months,3,NA,No QoL data,NA,NA,Moderate toxicity,NA,NA,NA,NA,NA,NA,12.03.2020,NA,12.03.2020,NA,NA,NA,NA,NA,NA,NA
177Lu-DOTATATE,Best supportive care + octreotide,Octreotide,"Progressive midgut neuroendocrine tumour on SSA, functional or non-functional; grade 1 or 2, SSTR positive",Endocrine Tumours,Neuroendocrine Tumour,Midgut,Advanced,4,NA,NA,https://www.nejm.org/doi/full/10.1056/nejmoa1607427,https://ascopubs.org/doi/full/10.1200/JCO.2018.78.5865?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,NA,Octreotide,NA,NA,NA,NA,Form 2b,PFS,"Progressive midgut neuroendocrine tumour on SSA, functional or non-functional; grade 1 or 2, SSTR positive ",NETTER-1,            Advanced    ,Midgut,Neuroendocrine Tumour,Endocrine Tumours,Best supportive care + octreotide,NA,0.21 (0.13-0.33),4,OS not mature,NA,NA,8.4 months,31.6 months (Calculated estimate of gain based on point estimate HR 0.21) ,3,1+,Improvement in QoL; favourable safety profile,NA,NA,NA,NA,NA,NA,NA,NA,NA,12.03.2020,NA,12.03.2020,NA,NA,NA,NA,NA,NA,NA
Brigatinib,-,Single arm study,222 patients enrolled: 112 patients  90mg vs 110 patients 180mg,Thoracic Malignancies,Non-small-cell Lung Cancer,ALK+,Advanced,3,NA,NA,https://ascopubs.org/doi/full/10.1200/JCO.2016.71.5904?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed,NA,NA,Single arm study,NA,NA,NA,NA,Form 3,ORR (Phase II) 180 mg,222 patients enrolled: 112 patients  90mg vs 110 patients 180mg,NA,            Advanced    ,ALK+,Non-small-cell Lung Cancer,Thoracic Malignancies,NA,NA,NA,3,NA,NA,NA,12.9 months,12 months,3,NA,NA,NA,NA,Tolerable toxicity,NA,NA,NA,NA,NA,NA,16.03.2020,54% achieved in ORR,16.03.2020,11.1 months,NA,NA,NA,NA,NA,NA
Pembrolizumab,Chemotherapy,Carboplatin and either paclitaxel or nab-paclitaxel,First line metastatic squamous non-small cell lung cancer,Thoracic Malignancies,Non-small-cell Lung Cancer,-,Advanced,4,NA,NA,https://www.nejm.org/doi/full/10.1056/NEJMoa1810865?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,https://ascopubs.org/doi/pdf/10.1200/JCO.19.01348,NA,Carboplatin and either paclitaxel or nab-paclitaxel,NA,NA,NA,NA,Form 2a,"OS, PFS",First line metastatic squamous non-small cell lung cancer ,KEYNOTE-407,            Advanced    ,NA,Non-small-cell Lung Cancer,Thoracic Malignancies,Chemotherapy,NA,0.56 (0.45-0.70) ,4,11.3 months,4.6 months,0.64 (0.49–0.85),4.8 months,1.6 months,4,NA,Delayed deterioration (exploratory outcome not eligible for upgrade),30.04.2020,NA,Similar toxicity,NA,NA,NA,NA,NA,NA,16.03.2020,NA,16.03.2020,NA,NA,NA,NA,NA,NA,NA
Atezolizumab,Chemotherapy + bevacizumab,"Bevacizumab, paclitaxel and carboplatin",First-line treatment of metastatic non-squamous NSCLC,Thoracic Malignancies,Non-small-cell Lung Cancer,WT Population,Metastatic,3,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1716948?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dwww.ncbi.nlm.nih.gov,NA,NA,"Bevacizumab, paclitaxel and carboplatin",NA,NA,NA,NA,Form 2a,PFS/OS,First-line treatment of metastatic non-squamous NSCLC  ,IMpower150,            Metastatic    ,WT Population,Non-small-cell Lung Cancer,Thoracic Malignancies,Chemotherapy + bevacizumab,NA,062 (0.52-0.74),3,14.7 months,4.5 months,0.78 (0.64-0.96),6.8 months,1.5 months,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,16.03.2020,NA,16.03.2020,NA,NA,NA,NA,NA,NA,NA
Atezolizumab,Chemotherapy + bevacizumab,"Bevacizumab, paclitaxel and carboplatin",First-line treatment of metastatic non-squamous NSCLC,Thoracic Malignancies,Non-small-cell Lung Cancer,EGFR+,Metastatic,3,NA,NA,https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(19)30084-0/fulltext,NA,NA,"Bevacizumab, paclitaxel and carboplatin",NA,NA,NA,NA,Form 2b,PFS,First-line treatment of metastatic non-squamous NSCLC  ,IMpower150,            Metastatic    ,EGFR+,Non-small-cell Lung Cancer,Thoracic Malignancies,Chemotherapy + bevacizumab,NA,0.59 (0.37–0.94) ,3,NA,NA,NA,6.1 months,3.1 months,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,16.03.2020,NA,16.03.2020,NA,NA,NA,NA,NA,NA,NA
Atezolizumab,Carboplatin plus nab-paclitaxel,Carboplatin plus nab-paclitaxel,First-line treatment of metastatic non-squamous NSCLC,Thoracic Malignancies,Non-small-cell Lung Cancer,-,Metastatic,3,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30167-6/fulltext,NA,NA,Carboplatin plus nab-paclitaxel,NA,NA,NA,NA,Form 2a,PFS/OS,First-line treatment of metastatic non-squamous NSCLC  ,IMpower130,            Metastatic    ,NA,Non-small-cell Lung Cancer,Thoracic Malignancies,Carboplatin plus nab-paclitaxel,NA,0.64 (0.54-0.77),3,13.9 months,4.7 months,0.79 (0.64-0.98),5.5 months,1.5 months,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,16.03.2020,NA,16.03.2020,NA,NA,NA,NA,NA,NA,NA
Ribociclib,Endocrine therapy,Placebo + endocrine therapy,"1st line premenopausal HR+, HER2-",Breast Cancer,Breast Cancer,HR+ HER2-,Metastatic,5,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30292-4/fulltext,https://www.nejm.org/doi/full/10.1056/NEJMoa1903765?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385843/,Placebo + endocrine therapy,NA,NA,NA,NA,Form 2a,PFS,"1st line premenopausal HR+, HER2-",MONALEESA-7,            Metastatic    ,HR+ HER2-,Breast Cancer,Breast Cancer,Endocrine therapy,NA,0.55 (0.44-0.69),5,40.9 months ,16 months (Calculated estimate of gain based on PE HR 0.71),0.71 (0.54-0.95),13.0 months,10.8 months,4,1+,Delayed deterioration,21.08.2020,NA,Serious adverse effects 18% vs 12%,NA,OS,NA,NA,NA,NA,20.04.2020,NA,20.04.2020,NA,NA,NA,NA,NA,NA,NA
Abemaciclib,Aromatase inhibitor,Placebo,"1st line postmenopausal HR+, HER2-",Breast Cancer,Breast Cancer,HR+ HER2-,Locally advanced or metastatic,3,NA,NA,http://ascopubs.org/doi/full/10.1200/JCO.2017.75.6155,NA,NA,Placebo,NA,NA,NA,NA,Form 2b,PFS,"1st line postmenopausal HR+, HER2-",MONARCH 3,            Locally advanced or metastatic    ,HR+ HER2-,Breast Cancer,Breast Cancer,Aromatase inhibitor ,NA,0.54 (0.41-0.72),3,NA,NA,NA,14.7 months,12.5 months (Calculated estimate of gain based on PE HR 0.54),3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,20.04.2020,NA,20.04.2020,NA,NA,NA,NA,NA,NA,NA
Abemaciclib,Fulvestrant,Placebo,"2nd line postmenopausal HR+, ERBB2-",Breast Cancer,Breast Cancer,HR+ ERBB2-,Advanced,4,NA,NA,http://ascopubs.org/doi/full/10.1200/JCO.2017.73.7585?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed ,https://jamanetwork.com/journals/jamaoncology/fullarticle/2752266,NA,Placebo,NA,NA,NA,NA,Form 2a,PFS,"2nd line postmenopausal HR+, ERBB2-",MONARCH 2,            Advanced    ,HR+ ERBB2-,Breast Cancer,Breast Cancer,Fulvestrant,NA,0.55 (0.45-0.68),4,37.3 months,9.4 months,0.76 (0.61-0.95),9.3 months,7.1 months,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,20.04.2020,NA,20.04.2020,NA,NA,NA,NA,NA,NA,NA
Ribociclib,Fulvestrant,Placebo + fulvestrant,1st or 2nd line metastatic post-menopause ER/PR+,Breast Cancer,Breast Cancer,ER/PR+,Metastatic,4,NA,NA,https://ascopubs.org/doi/full/10.1200/JCO.2018.78.9909?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed,https://www.nejm.org/doi/10.1056/NEJMoa1911149,NA,Placebo + fulvestrant,NA,NA,NA,NA,Form 2a,PFS,1st or 2nd line metastatic post-menopause ER/PR+ ,MONALEESA-3,            Metastatic    ,ER/PR+,Breast Cancer,Breast Cancer,Fulvestrant,NA,0.59 (0.48-0.73),4,40.0 months,15.6 months (Calculated estimate of gain based on PE HR 0.72),0.72 (0.57-0.92),12.8 months,7.7 months,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,20.04.2020,NA,20.04.2020,NA,NA,NA,NA,NA,NA,NA
Fulvestrant,-,Anastrozole,"Post-menopausal women not previously treated with endocrine therapy, or with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy",Breast Cancer,Breast Cancer,ER+,Locally advanced or metastatic,2,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32389-3/fulltext,NA,NA,Anastrozole,NA,NA,NA,NA,Form 2b,PFS,"Post-menopausal women not previously treated with endocrine therapy, or with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy",FALCON,            Locally advanced or metastatic    ,ER+,Breast Cancer,Breast Cancer,NA,NA,0.80 (0.64-1.00),2,NA,NA,NA,13.8 months,2.8 months,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,20.04.2020,NA,20.04.2020,NA,NA,NA,NA,NA,NA,NA
Alpelisib,Fulvestrant,Placebo + fulvestrant,2nd line postmenopausal PIK3CA-mutated HR+ HER2-,Breast Cancer,Breast Cancer,PIK3CA-mutated HR+ HER2-,Advanced,3,NA,NA,https://www.nejm.org/doi/full/10.1056/NEJMoa1813904,NA,NA,Placebo + fulvestrant,NA,NA,NA,NA,Form 2b,PFS,2nd line postmenopausal PIK3CA-mutated HR+ HER2-  ,SOLAR-1,            Advanced    ,PIK3CA-mutated HR+ HER2-,Breast Cancer,Breast Cancer,Fulvestrant,NA,0.65 (0.50-0.85),3,NA,NA,NA,5.7 months,5.3 months,3,NA,NA,06.08.2020,NA,NA,NA,NA,NA,NA,NA,NA,20.04.2020,NA,20.04.2020,NA,NA,NA,NA,NA,NA,NA
Trastuzumab deruxtecan,-,Single arm study,Unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based treatments,Breast Cancer,Breast Cancer,HER2+,Unresectable or metastatic,2,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1914510,NA,NA,Single arm study,NA,NA,NA,NA,Form 3,ORR (Phase II)  ,Unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based treatments,DESTINY-Breast01,            Unresectable or metastatic    ,HER2+,Breast Cancer,Breast Cancer,NA,NA,NA,2,NA,NA,NA,16.4 months,NA,3,NA,NA,NA,1-,52.2% Grade 3+ toxicity 2% toxic fatalities,NA,NA,NA,Approved by the FDA awaiting EMA approval,NA,NA,20.04.2020,60.9%,20.04.2020,14.8 months,NA,NA,NA,NA,NA,NA
Talazoparib,-,Standard chemotherapy,Post anathacycline and taxane,Breast Cancer,Breast Cancer,HER2- g-BrCa+ve,Advanced,4,NA,NA,https://www.nejm.org/doi/full/10.1056/NEJMoa1802905,https://www.annalsofoncology.org/article/S0923-7534(19)34176-6/fulltext,NA,Standard chemotherapy,NA,NA,NA,NA,Form 2b,PFS,Post anathacycline and taxane,EMBRACA,            Advanced    ,HER2- g-BrCa+ve,Breast Cancer,Breast Cancer,NA,NA,0.54 (0.41-0.71),4,NA,NA,NA,5.6 months,3 months,3,1+,Improved,NA,NA,NA,NA,NA,NA,NA,NA,NA,20.04.2020,NA,20.04.2020,NA,NA,NA,NA,NA,NA,NA
Olaparib,-,Standard chemotherapy,<2 previous chemotherapy regimens,Breast Cancer,Breast Cancer,HER2- g-BrCa+ve,Metastatic,4,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1706450?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,https://www.annalsofoncology.org/article/S0923-7534(19)31111-1/fulltext,NA,Standard chemotherapy,NA,NA,NA,NA,Form 2b,PFS,<2 previous chemotherapy regimens ,OlympiAD,            Metastatic    ,HER2- g-BrCa+ve,Breast Cancer,Breast Cancer,NA,NA,0.58 (0.43-0.80),4,17.1 months,2.2 months,Not significant ,4.2 months,2.8 months,3,NA,Pending,NA,1+,Reduced,NA,NA,NA,NA,NA,NA,20.04.2020,NA,20.04.2020,NA,NA,NA,NA,NA,NA,NA
Tucatinib,Trastuzumab + capecitabine,"Placebo, trastuzumab + capecitabine","Disease progression after therapy with trastuzumab, pertuzumab and trastuzumab entansine",Breast Cancer,Breast Cancer,HER2+,Metastatic,3,NA,NA,https://www.nejm.org/doi/pdf/10.1056/NEJMoa1914609,NA,NA,"Placebo, trastuzumab + capecitabine",NA,NA,NA,NA,Form 2a,Primary: PFS on first 480 randomized  - Secondary: OS on total 612 randomized ,"Disease progression after therapy with trastuzumab, pertuzumab and trastuzumab entansine",HER2CLIMB,            Metastatic    ,HER2+,Breast Cancer,Breast Cancer,Trastuzumab + capecitabine,NA,0.54 (0.42-0.71),3,17.4 months,4.5 months,0.66 (050-0.88),5.6 months,2.2 months,3,NA,NA,NA,NA,NA,NA,NA,NA,Approved by the FDA awaiting EMA approval ,NA,NA,20.04.2020,NA,20.04.2020,NA,NA,NA,NA,NA,NA,NA
Binimetinib,Encorafenib,Vemurafenib,Advanced unresectable or metastatic melanoma with  BRAF V600,Skin Cancers,Melanoma,BRAF V600,Unresectable or metastatic,4,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30497-2/fulltext,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30142-6/fulltext,NA,Vemurafenib,NA,NA,NA,NA,Form 2a,PFS and OS,Advanced unresectable or metastatic melanoma with  BRAF V600 ,COLUMBUS,            Unresectable or metastatic    ,BRAF V600,Melanoma,Skin Cancers,Encorafenib,NA,0.51 (0.39-0.67),4,16.9 months,16.7 months,0.61 (0.47-0.79),7.3 months,7.6 months,4,NA,NA,23.07.2020,NA,NA,NA,OS,NA,NA,NA,NA,21.04.2020,NA,21.04.2020,NA,NA,NA,NA,NA,NA,NA
Ramucirumab,Erlotinib,Placebo + Erlotinib,1st line treatment of NSCLC with EGFR mutation,Thoracic Malignancies,Non-small-cell Lung Cancer,EGFR+,Metastatic,3,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30634-5/fulltext,NA,NA,Placebo + Erlotinib,NA,NA,NA,NA,Form 2b,PFS,1st line treatment of NSCLC with EGFR mutation,RELAY,            Metastatic    ,EGFR+,Non-small-cell Lung Cancer,Thoracic Malignancies,Erlotinib,NA,0.59 (0.46-0.76),3,NA,NA,NA,12.4 months,7 months,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,22.04.2020,NA,22.04.2020,NA,NA,NA,NA,NA,NA,NA
Durvalumab,-,Placebo,Consolidation therapy in patients with stage III NSCLC who did not have disease progression after two or more cycles of platinum-based chemo radiotherapy,Thoracic Malignancies,Non-small-cell Lung Cancer,-,Locally advanced,4,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1709937?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,https://www.nejm.org/doi/full/10.1056/NEJMoa1809697?query=featured_home,https://www.sciencedirect.com/science/article/pii/S1556086419335294,Placebo,NA,NA,NA,NA,Form 2a,PFS ITT population across all PD-L1 categories,Consolidation therapy in patients with stage III NSCLC who did not have disease progression after two or more cycles of platinum-based chemo radiotherapy ,PACIFIC,            Locally advanced    ,NA,Non-small-cell Lung Cancer,Thoracic Malignancies,NA,NA,0.52 (0.42-0.65),4,28.7 months   2-year OS survival: 55.6%,13 months (Calculated estimate of gain based on PE HR 0.68)  2-year OS gain: 10.7%,0.68 (0.53-0.875),5.6 months,11.2 months,4,NA,No benefit observed,NA,NA,NA,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30519-4/fulltext,NA,NA,NA,27.04.2020,NA,27.04.2020,NA,NA,NA,NA,NA,NA,NA
Atezolizumab,Nab-paclitaxel,Placebo + nab-paclitaxel,1st line treatment for unresectable locally advanced or metastatic triple-negative breast cancer,Breast Cancer,Breast Cancer,PD-L1+,Locally advanced or metastatic,3,NA,NA,https://www.nejm.org/doi/full/10.1056/NEJMoa1809615,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30689-8/fulltext,https://www.annalsofoncology.org/article/S0923-7534(20)36038-5/pdf,Placebo + nab-paclitaxel,NA,NA,NA,NA,Form 2b,PFS stratified for PD-L1+,1st line treatment for unresectable locally advanced or metastatic triple-negative breast cancer,IMpassion130,            Locally advanced or metastatic    ,PD-L1+,Breast Cancer,Breast Cancer,Nab-paclitaxel,NA,0.62 (0.49-0.78),3,18.0 months,7.0 months,0.74 (0.54-0.94) *Exploratory unplanned post hoc analysis not eligible for ESMO-MCBS grading ,5.0 months,2.5 months,3,NA,No benefit observed,NA,NA,NA,NA,NA,NA,NA,NA,NA,13.05.2020,NA,13.05.2020,NA,NA,NA,NA,NA,NA,NA
Dabrafenib,Trametinib,Placebo,Adjuvant treatment of melanoma after surgical resection. BRAF V600 mutation,Skin Cancers,Melanoma,BRAF+,Adjuvant,A,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1708539?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov,https://ascopubs.org/doi/full/10.1200/JCO.18.01219?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30940-9/fulltext,Placebo,NA,NA,NA,A,Form 1,RFS,Adjuvant treatment of melanoma after surgical resection. BRAF V600 mutation ,COMBI-AD,            Adjuvant    ,BRAF+,Melanoma,Skin Cancers,Trametinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,QoL reported (exploratory outcome)*,23.07.2020,NA,NA,NA,NA,NA,*QoL evaluated as an exploratory endpoint  (as distinct from primary or secondary endpoint) is not eligible for ESMO-MCBS grading,NA,NA,09.06.2020,NA,09.06.2020,NA,NA,NA,16.6 months 3-years 39%,27.9 months 3-years 19%,0.47 (0.39-0.58),NA
Pembrolizumab,-,Placebo,Adjuvant treatment of adults with stage III melanoma and lymph node involvement after complete resection,Skin Cancers,Melanoma,-,Adjuvant,A,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1802357?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov,https://jamanetwork.com/journals/jamaoncology/fullarticle/2757843,NA,Placebo,NA,NA,NA,A,Form 1,RFS,Adjuvant treatment of adults with stage III melanoma and lymph node involvement after complete resection,MK-2475-054/4658-MG/KEYNOTE-054,            Adjuvant    ,NA,Melanoma,Skin Cancers,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,23.07.2020,NA,Higher incidence of acute and persisting adverse effects,NA,RFS,NA,NA,NA,NA,09.06.2020,NA,09.06.2020,NA,NA,NA,1-year 61%,1-year 14.4%,0.57 (0.43-0.74),NA
Nivolumab,-,Ipilimumab 10mg/kg,Adult patients with complete resection of stage IIIB/C or IV melanoma,Skin Cancers,Melanoma,-,Adjuvant,A,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1709030?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov,NA,NA,Ipilimumab 10mg/kg,NA,NA,NA,A,Form 1,RFS,Adult patients with complete resection of stage IIIB/C or IV melanoma,CheckMate 238,            Adjuvant    ,NA,Melanoma,Skin Cancers,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Fewer treatment-related grade 3 or 4 adverse events 14.4% versus 45.9%,NA,RFS,NA,NA,NA,NA,09.06.2020,NA,09.06.2020,NA,NA,NA,1-year 60.8%,1-year 9.7%,0.66 (0.53-0.81),NA
Abiraterone,Prednisone + ADT (androgen deprivation therapy),ADT + placebo,Treatment of newly diagnosed high risk mHSPC in adult men in combination with ADT,Genitourinary Cancers,Prostate cancer,-,High Risk,4,NA,NA,https://www.nejm.org/doi/10.1056/NEJMoa1704174?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30082-8/fulltext,NA,ADT + placebo,NA,NA,NA,NA,Form 2a,OS and PFS,Treatment of newly diagnosed high risk mHSPC in adult men in combination with ADT,LATITUDE,            High Risk    ,NA,Prostate cancer,Genitourinary Cancers,Prednisone + ADT (androgen deprivation therapy),NA,0.47 (0.39-0.55),4,36.5 months,16.8 months,0.66 (0.56-0.78),14.8 months,18.2 months,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,10.06.2020,NA,10.06.2020,NA,NA,NA,NA,NA,NA,NA
Apalutamide,ADT (androgen deprivation therapy),ADT + placebo,Treatment of non-metastatic CRPC who are at high risk of developing metastatic disease in combination with ADT,Genitourinary Cancers,Prostate cancer,-,High Risk,3,NA,NA,https://www.nejm.org/doi/full/10.1056/NEJMoa1715546,NA,NA,ADT + placebo,NA,NA,NA,NA,Form 2b (Scoring of MFS on the same basis as PFS),MFS,Treatment of non-metastatic CRPC who are at high risk of developing metastatic disease in combination with ADT,SPARTAN,            High Risk    ,NA,Prostate cancer,Genitourinary Cancers,ADT (androgen deprivation therapy),NA,0.28 (0.23-0.35),3,NA,NA,NA,16.2 months,24.3 months,3,NA,NA,NA,NA,NA,NA,MFS,NA,NA,NA,NA,19.06.2020,NA,19.06.2020,NA,NA,NA,NA,NA,NA,NA
Abiraterone,Prednisone + ADT (androgen deprivation therapy),ADT + placebo,"First-line, high risk, serologic relapsed and metastatic, castration-sensitive prostate cancer in combination with ADT",Genitourinary Cancers,Prostate cancer,-,High Risk,4,NA,NA,https://www.nejm.org/doi/full/10.1056/NEJMoa1702900,NA,NA,ADT + placebo,NA,NA,NA,NA,Form 2b (Scoring of FFS on the same basis as PFS),FFS,"First-line, high risk, serologic relapsed and metastatic, castration-sensitive prostate cancer in combination with ADT",STAMPEDE,            High Risk    ,NA,Prostate cancer,Genitourinary Cancers,Prednisone + ADT (androgen deprivation therapy),NA,0.29 (0.25-0.34),4,NA,NA,NA,24.0 months (Estimated from Kaplan Meier Plot),58.0 months (Calculated estimate of gain based on PE HR 0.29),3,NA,NA,NA,NA,NA,NA,FFS,NA,NA,NA,NA,19.06.2020,NA,19.06.2020,NA,NA,NA,NA,NA,NA,1+
Enzalutamide,ADT (androgen deprivation therapy),ADT,First-line metastatic hormone-sensitive prostate cancer combined with ADT,Genitourinary Cancers,Prostate cancer,-,Metastatic,4,NA,NA,https://www.nejm.org/doi/full/10.1056/NEJMoa1903835,NA,NA,ADT,NA,NA,NA,NA,"Form 2b (Form 2a cannot be applied since median OS not reached in the control arm, consequently, score derived from form 2b criteria with an upgrade for early stopping based on OS advantage detected at interim analysis)",OS,First-line metastatic hormone-sensitive prostate cancer combined with ADT,ENZAMET,            Metastatic    ,NA,Prostate cancer,Genitourinary Cancers,ADT (androgen deprivation therapy),NA,0.40 (0.33-0.49),4,72% at 3-years,8% at 3-years,0.67 (0.52-0.86) interim OS (p=0.002 <0.003 threshold for interim analysis),24 months (Estimated from Kaplan Meier Plot),36 months (Calculated estimate of gain based on PE HR 0.40),3,NA,NA,NA,NA,NA,NA,PFS,NA,NA,NA,NA,30.06.2020,NA,30.06.2020,NA,NA,NA,NA,NA,NA,1+
Enzalutamide,ADT (androgen deprivation therapy),ADT + placebo,Non-metastatic CRPC with PSA doubling time <10 months combined with ADT,Genitourinary Cancers,Prostate cancer,-,Non-metastatic,3,NA,NA,https://www.nejm.org/doi/full/10.1056/NEJMoa1800536,NA,NA,ADT + placebo,NA,NA,NA,NA,Form 2b (Scoring of MFS on the same basis as PFS),MFS,Non-metastatic CRPC with PSA doubling time <10 months combined with ADT,PROSPER,            Non-metastatic    ,NA,Prostate cancer,Genitourinary Cancers,ADT (androgen deprivation therapy),NA,0.29 (0.24-0.35),3,NA,NA,NA,14.7 months,21.9 months,3,NA,NA,NA,NA,NA,NA,MFS,NA,NA,NA,NA,30.06.2020,NA,30.06.2020,NA,NA,NA,NA,NA,NA,NA
Docetaxel,ADT (androgen deprivation therapy),ADT,Treatment for metastatic CRPC combined with ADT,Genitourinary Cancers,Prostate cancer,-,Metastatic,4,NA,NA,https://www.nejm.org/doi/full/10.1056/NEJMoa1503747,https://ascopubs.org/doi/full/10.1200/JCO.2017.75.3657?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed,https://ascopubs.org/doi/full/10.1200/JCO.2017.75.3335?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed,ADT,NA,NA,NA,NA,Form 2a,OS high volume disease control,Treatment for metastatic CRPC combined with ADT,CHAARTED,            Metastatic    ,NA,Prostate cancer,Genitourinary Cancers,ADT (androgen deprivation therapy),NA,NA,4,34.4 months,16.8 months,0.63 (0.50-0.79),NA,NA,4,NA,Not creditable (Benefits observed were less than the described threshold for clinical significance),NA,NA,NA,NA,OS,NA,NA,NA,NA,30.06.2020,NA,30.06.2020,NA,NA,NA,NA,NA,NA,NA
Docetaxel,ADT (androgen deprivation therapy),ADT,Treatment for metastatic CRPC combined with ADT,Genitourinary Cancers,Prostate cancer,-,Metastatic,4,NA,NA,https://www.nejm.org/doi/full/10.1056/NEJMoa1503747,https://ascopubs.org/doi/full/10.1200/JCO.2017.75.3657?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed,https://ascopubs.org/doi/full/10.1200/JCO.2017.75.3335?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed,ADT,NA,NA,NA,NA,Form 2a,OS ITT,Treatment for metastatic CRPC combined with ADT,CHAARTED,            Metastatic    ,NA,Prostate cancer,Genitourinary Cancers,ADT (androgen deprivation therapy),NA,NA,4, 47.2 months,10.4 months ,0.72 (0.59-0.89),NA,NA,4,NA,Not creditable (Benefits observed were less than the described threshold for clinical significance),NA,NA,NA,NA,OS,NA,NA,NA,NA,30.06.2020,NA,30.06.2020,NA,NA,NA,NA,NA,NA,NA
Docetaxel,ADT (androgen deprivation therapy),ADT,"First-line long-term hormone therapy for high-risk locally advanced, metastatic or recurrent combined with ADT",Genitourinary Cancers,Prostate cancer,-,High-risk locally advanced,4,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01037-5/fulltext,NA,NA,ADT,NA,NA,NA,NA,Form 2a,OS,"First-line long-term hormone therapy for high-risk locally advanced, metastatic or recurrent combined with ADT",STAMPEDE,            High-risk locally advanced    ,NA,Prostate cancer,Genitourinary Cancers,ADT (androgen deprivation therapy),NA,NA,4,71.0 months,10.0 months,0.78 (0.66-0.93),NA,NA,4,NA,NA,NA,NA,Grade 3+ 52% versus 32%,NA,OS,NA,NA,NA,NA,30.06.2020,NA,30.06.2020,NA,NA,NA,NA,NA,NA,NA
Darolutamide,ADT (androgen deprivation therapy),ADT + placebo,Non-metastatic castration resistant prostate cancer for adult men who are at high risk of developing metastatic disease. PSA doubling time of <10 months combined with ADT,Genitourinary Cancers,Prostate cancer,-,Non-metastatic,3,NA,NA,https://www.nejm.org/doi/full/10.1056/NEJMoa1815671,NA,NA,ADT + placebo,NA,NA,NA,NA,Form 2b (Scoring of MFS on the same basis as PFS),MFS,Non-metastatic castration resistant prostate cancer for adult men who are at high risk of developing metastatic disease. PSA doubling time of <10 months combined with ADT,ARAMIS,            Non-metastatic    ,NA,Prostate cancer,Genitourinary Cancers,ADT (androgen deprivation therapy),NA,0.41 (0.34-0.50),3,NA,NA,NA,18.4 months,22.0 months,3,NA,NA,NA,NA,NA,NA,MFS,NA,NA,NA,NA,01.07.2020,NA,01.07.2020,NA,NA,NA,NA,NA,NA,NA
Apalutamide,ADT (androgen deprivation therapy),ADT + placebo,Treatment of Metastatic CSPC in combination with ADT,Genitourinary Cancers,Prostate cancer,-,Metastatic,4,NA,NA,https://www.nejm.org/doi/full/10.1056/NEJMoa1903307,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30620-5/fulltext,NA,ADT + placebo,NA,NA,NA,NA,"Form 2b (Form 2a cannot be applied since median OS not reached in the control arm, consequently, score derived from form 2b criteria with an upgrade for early stopping based on OS advantage detected at interim analysis)",PFS/OS,Treatment of Metastatic CSPC in combination with ADT,TITAN,            Metastatic    ,NA,Prostate cancer,Genitourinary Cancers,ADT (androgen deprivation therapy),NA,0.48 (0.39-0.60),4,74% at 2-years,8% at 2-years, 0.67 (0.51-0.89) interim OS (p=0.005 <0.009 threshold for interim analysis) ,22.1 months,23.0 months (Calculated estimate of gain based on PE HR 0.48),3,NA,No benefit,NA,NA,Ischemic heart disease 4.4% versus 1.5%,NA,PFS,NA,NA,NA,NA,01.07.2020,NA,01.07.2020,NA,NA,NA,NA,NA,NA,1+
Pasireotide,-,Single arm study,Advanced carcinoids of the lung and thymus,Endocrine Tumours,Neuroendocrine Tumour,Lung and thymic carcinoids,Advanced,3,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30681-2/fulltext,NA,NA,Single arm study,NA,NA,NA,NA,Form 3,PFS (Phase II),Advanced carcinoids of the lung and thymus,LUNA,            Advanced    ,Lung and thymic carcinoids,Neuroendocrine Tumour,Endocrine Tumours,NA,NA,NA,3,NA,NA,NA,NA,8.5 months,3,NA,No data,NA,NA,NA,NA,PFS,NA,NA,NA,NA,14.07.2020,NA,14.07.2020,NA,NA,NA,NA,NA,NA,NA
Everolimus,-,Single arm study,Advanced carcinoids of the lung and thymus,Endocrine Tumours,Neuroendocrine Tumour,Lung and thymic carcinoids,Advanced,3,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30681-2/fulltext,NA,NA,Single arm study ,NA,NA,NA,NA,Form 3,PFS (Phase II),Advanced carcinoids of the lung and thymus,LUNA,            Advanced    ,Lung and thymic carcinoids,Neuroendocrine Tumour,Endocrine Tumours,NA,NA,NA,3,NA,NA,NA,NA,12.5 months,3,NA,No data,NA,NA,NA,NA,PFS,NA,NA,NA,NA,14.07.2020,NA,14.07.2020,NA,NA,NA,NA,NA,NA,NA
Everolimus,Pasireotide,Single arm study,Advanced carcinoids of the lung and thymus,Endocrine Tumours,Neuroendocrine Tumour,Lung and thymic carcinoids,Advanced,2,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30681-2/fulltext,NA,NA,Single arm study,NA,NA,NA,NA,Form 3,PFS (Phase II),Advanced carcinoids of the lung and thymus,LUNA,            Advanced    ,Lung and thymic carcinoids,Neuroendocrine Tumour,Endocrine Tumours,Pasireotide,NA,NA,2,NA,NA,NA,NA,11.8 months,3,NA,No data,NA,1-,>30% grade 3-4 toxicities impacting on daily well-being,NA,PFS,NA,NA,NA,NA,14.07.2020,NA,14.07.2020,NA,NA,NA,NA,NA,NA,NA
Cetuximab,Cisplatin or carboplatin plus 5-FU,Cisplatin or carboplatin plus 5-FU,First-line treatment of patients with recurrent or metastatic SCCHN,Head and neck cancer,Squamous cell,-,Recurrent or metastatic,3,NA,NA,https://www.nejm.org/doi/full/10.1056/NEJMoa0802656,https://www.annalsofoncology.org/article/S0923-7534(19)39580-8/abstract,NA,Cisplatin or carboplatin plus 5-FU,NA,NA,NA,NA,Form 2a,OS,First-line treatment of patients with recurrent or metastatic SCCHN,NA,            Recurrent or metastatic    ,NA,Squamous cell,Head and neck cancer,Cisplatin or carboplatin plus 5-FU,NA,NA,3,7.4 months,2.7 months,0.80 (0.64-0.99),NA,NA,3,NA,No benefit observed,NA,NA,NA,NA,OS,NA,NA,NA,NA,15.07.2020,NA,15.07.2020,NA,NA,NA,NA,NA,NA,NA
Nivolumab,-,Investigator choice (methotrexate or cetuximab or docetaxel),Treatment of patients with recurrent SCCHN,Head and neck cancer,Squamous cell,-,Recurrent,4,NA,NA,https://www.nejm.org/doi/full/10.1056/NEJMoa1602252,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30421-7/fulltext,NA,Investigator choice (methotrexate or cetuximab or docetaxel),NA,NA,NA,NA,Form 2a,OS,Treatment of patients with recurrent SCCHN,CheckMate141,            Recurrent    ,NA,Squamous cell,Head and neck cancer,NA,NA,NA,4,5.1 months,2.4 months,0.70 (0.51-0.96),NA,NA,3,NA,"QoL improved (exploratory end point, therefore, not creditable)",NA,1+,Reduced toxicity,NA,OS,NA,NA,NA,NA,15.07.2020,NA,15.07.2020,NA,NA,NA,NA,NA,NA,NA
Rucaparib,-,Single arm (Phase II),"Platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy.",Gynaecological Malignancies,"Ovarian, fallopian tubes and peritoneum cancer",BRCA mutation,Relapsed or progressive,3,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30559-9/fulltext,https://ijgc.bmj.com/content/29/9/1396.long,NA,Single arm (Phase II),NA,NA,NA,NA,Form 3,ORR ,"Platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy.                 ",ARIEL2,            Relapsed or progressive    ,BRCA mutation,"Ovarian, fallopian tubes and peritoneum cancer",Gynaecological Malignancies,NA,NA,NA,3,NA,NA,NA,12.8 months,NA,3,NA,NA,NA,NA,NA,NA,ORR,NA,NA,NA,NA,17.07.2020,80%,17.07.2020,9.2 months,NA,NA,NA,NA,NA,NA
Rucaparib,-,Placebo,"Maintenance treatment of patients with platinum sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy",Gynaecological Malignancies,"Ovarian, fallopian tubes and peritoneum cancer",Homologous recombination deficiencies (HRD) (BRCA mutant or BRCA wild-type and high loss of heterozygosity),Relapsed high grade,3,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32440-6/fulltext,https://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(20)30061-9.pdf,NA,Placebo,NA,NA,NA,NA,Form 2b,PFS,"Maintenance treatment of patients with platinum sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy",ARIEL3,            Relapsed high grade    ,Homologous recombination deficiencies (HRD) (BRCA mutant or BRCA wild-type and high loss of heterozygosity),"Ovarian, fallopian tubes and peritoneum cancer",Gynaecological Malignancies,NA,NA,0.32 (0.24-0.42),3,NA,NA,NA,5.4 months,8.2 months,3,NA,NA,NA,NA,NA,NA,PFS,NA,NA,NA,NA,17.07.2020,NA,17.07.2020,NA,NA,NA,NA,NA,NA,NA
Rucaparib,-,Placebo,"Maintenance treatment of patients with platinum sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy",Gynaecological Malignancies,"Ovarian, fallopian tubes and peritoneum cancer",Germline or somatic - BRCA mutation,Relapsed high grade,3,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32440-6/fulltext,https://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(20)30061-9.pdf,NA,Placebo,NA,NA,NA,NA,Form 2b,PFS,"Maintenance treatment of patients with platinum sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy",ARIEL3,            Relapsed high grade    ,Germline or somatic - BRCA mutation,"Ovarian, fallopian tubes and peritoneum cancer",Gynaecological Malignancies,NA,NA,0.23 (0.16-0.34),3,NA,NA,NA,5.4 months,11.2 months,3,NA,NA,NA,NA,NA,NA,PFS,NA,NA,NA,NA,17.07.2020,NA,17.07.2020,NA,NA,NA,NA,NA,NA,NA
Rucaparib,-,Placebo,"Maintenance treatment of patients with platinum sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy",Gynaecological Malignancies,"Ovarian, fallopian tubes and peritoneum cancer",ITT population (ALL),Relapsed high grade,3,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32440-6/fulltext,https://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(20)30061-9.pdf,NA,Placebo,NA,NA,NA,NA,Form 2b,PFS,"Maintenance treatment of patients with platinum sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy",ARIEL3,            Relapsed high grade    ,ITT population (ALL),"Ovarian, fallopian tubes and peritoneum cancer",Gynaecological Malignancies,NA,NA,0.36 (0.30-0.45),3,NA,NA,NA,5.4 months,5.4 months,3,NA,NA,NA,NA,NA,NA,PFS,NA,NA,NA,NA,17.07.2020,NA,17.07.2020,NA,NA,NA,NA,NA,NA,NA
Atezolizumab,Carboplatin and etoposide,Placebo plus carboplatin and etoposide,First-line treatment of extensive-stage SCLC,Thoracic Malignancies,Small-cell Lung Cancer,-,Extensive-stage,3,NA,NA,https://www.nejm.org/doi/full/10.1056/NEJMoa1809064,NA,NA,Placebo plus carboplatin and etoposide,NA,NA,NA,NA,Form 2a,PFS/OS,First-line treatment of extensive-stage SCLC,IMpower133,            Extensive-stage    ,NA,Small-cell Lung Cancer,Thoracic Malignancies,Carboplatin and etoposide ,NA,0.77 (0.62-0.96),3,10.3 months,2.0 months,0.70 (0.54-0.91),4.3 months,0.9 months,3,NA,NA,NA,NA,NA,NA,OS,NA,NA,NA,NA,17.07.2020,NA,17.07.2020,NA,NA,NA,NA,NA,NA,NA
Pembrolizumab,-,Cisplatin or carboplatin/5-FU/cetuximab,Untreated locally incurable recurrent or metastatic SCCHN with CPS PD-L1 expression ≥1,Head and neck cancer,Squamous cell,CPS PD-L1 expression ≥1,Recurrent or metastatic,4,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32591-7/fulltext,NA,NA,Cisplatin or carboplatin/5-FU/cetuximab,NA,NA,NA,NA,Form 2a,PFS/OS,Untreated locally incurable recurrent or metastatic SCCHN with CPS PD-L1 expression ≥1,KEYNOTE-48,            Recurrent or metastatic    ,CPS PD-L1 expression ≥1,Squamous cell ,Head and neck cancer,NA,NA,NA,4,10.3 months,2.0 months,0.78 (0.64-0.96),NA,NA,3,NA,Pending,NA,1+,Reduced toxicity,NA,OS,NA,NA,NA,NA,17.07.2020,NA,17.07.2020,NA,NA,NA,NA,NA,NA,NA
Pembrolizumab,-,Cisplatin or carboplatin/5-FU/cetuximab,Untreated locally incurable recurrent or metastatic squamous cell carcinoma with CPS PD-L1 expression ≥20,Head and neck cancer,Squamous cell,CPS PD-L1 expression ≥20,Recurrent or metastatic,5,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32591-7/fulltext,NA,NA,Cisplatin or carboplatin/5-FU/cetuximab,NA,NA,NA,NA,Form 2a ,PFS/OS,Untreated locally incurable recurrent or metastatic squamous cell carcinoma with CPS PD-L1 expression ≥20,KEYNOTE-48,            Recurrent or metastatic    ,CPS PD-L1 expression ≥20,Squamous cell ,Head and neck cancer,NA,NA,NA,5,10.7 months,4.2 months,0.61 (0.45-0.83),NA,NA,4,NA,Pending,NA,1+,Reduced toxicity,NA,OS,NA,The licensed indication is for CPS PD-L1 expression ≥1. This score relates to a planned subgroup illustrating enhanced benefit among a subset of the approved cohort with CPS PD- L1 expression ≥20.,NA,NA,17.07.2020,NA,17.07.2020,NA,NA,NA,NA,NA,NA,NA
Pembrolizumab,Cisplatin or carboplatin/5-FU,Cisplatin or carboplatin/5-FU/cetuximab,Untreated locally incurable recurrent or metastatic squamous cell carcinoma with CPS PD-L1 expression ≥1,Head and neck cancer,Squamous cell,CPS PD-L1 expression ≥1,Recurrent or metastatic,4,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32591-7/fulltext,NA,NA,Cisplatin or carboplatin/5-FU/cetuximab,NA,NA,NA,NA,Form 2a,PFS/OS,Untreated locally incurable recurrent or metastatic squamous cell carcinoma with CPS PD-L1 expression ≥1,KEYNOTE-48,            Recurrent or metastatic    ,CPS PD-L1 expression ≥1,Squamous cell ,Head and neck cancer,Cisplatin or carboplatin/5-FU,NA,NA,4,10.4 months,3.2 months,0.65 (0.53-0.80),NA,NA,4,NA,Pending,NA,NA,NA,NA,OS,NA,NA,NA,NA,20.07.2020,NA,20.07.2020,NA,NA,NA,NA,NA,NA,NA
Pembrolizumab,-,"Standard of care (methotrexate, docetaxel or cetuximab)","Treatment of patients with recurrent or metastatic SCCHN after previous platinum-containing chemotherapy with PD-L1 CPS expression ≥1*,**",Head and neck cancer,Squamous cell,CPS PD-L1 expression ≥1,Recurrent or metastatic,4,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31999-8/fulltext,https://academic.oup.com/jnci/article-abstract/doi/10.1093/jnci/djaa063/5837115?redirectedFrom=fulltext,NA,"Standard of care (methotrexate, docetaxel or cetuximab)",NA,NA,NA,NA,Form 2a,OS,"Treatment of patients with recurrent or metastatic SCCHN after previous platinum-containing chemotherapy with PD-L1 CPS expression ≥1*,**",KEYNOTE-40,            Recurrent or metastatic    ,CPS PD-L1 expression ≥1,Squamous cell ,Head and neck cancer,NA,NA,NA,4,7.1 months,1.6 months,0.74 (0.58-0.93),NA,NA,3,NA,QoL evaluated as exploratory end point (as distinct from primary or secondary end point) is not eligible for ESMO-MCBS grading.,NA,1+,Reduced toxicity,NA,OS,NA,"*EMA approval is restricted to PD-L1 ≥50% TPS. PD-L1 ≥1 CPS was a secondary end point eligible for ESMO-MCBS scoring.                                                                                                                                                                         
**EMA indication is restricted to recurrent or metastatic head and neck cancer with PD-L1 ≥50% TPS. This approval is based on an exploratory analysis with no adjustment for multiplicity in which the median OS control arm was 6.6 months, with a gain of 5.0 months (HR 0.53 ; (95% CI 0.35–0.81). Although exploratory analyses can be the basis for hypothesis generation or conjecture or even licensing approvals by regulatory authorities, since they are exploratory (as distinct from primary or secondary end points), they are not eligible for grading using ESMO-MCBS.   ",NA,NA,20.07.2020,NA,20.07.2020,NA,NA,NA,NA,NA,NA,NA
Sunitinib,-,Placebo,Advanced GIST 2nd line after imatinib,Sarcoma,Soft tissue,GIST,Advanced,3,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(06)69446-4/fulltext,NA,NA,Placebo,NA,NA,NA,NA,Form 2b (Scoring of TTP on the same basis as PFS),TTP (Crossover allowed),Advanced GIST 2nd line after imatinib,NA,            Advanced    ,GIST,Soft tissue,Sarcoma,NA,NA,0.33 (0.23-0.47),3,NA,NA,NA,6.4 weeks,20.9 weeks,3,NA,NA,NA,NA,NA,NA,TTP ,NA,NA,NA,NA,21.07.2020,NA,21.07.2020,NA,NA,NA,NA,NA,NA,NA
Regorafenib,-,Placebo,"3rd line after imatinib and sunitinib - patients with histologically confirmed, metastatic or unresectable GIST, with failure of at least previous imatinib and sunitinib",Sarcoma,Soft tissue,GIST,Unresectable or metastatic,3,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140673612618571/fulltext,NA,NA,Placebo,NA,NA,NA,NA,Form 2b,PFS (Crossover allowed),"3rd line after imatinib and sunitinib - patients with histologically confirmed, metastatic or unresectable GIST, with failure of at least previous imatinib and sunitinib ",GRID,            Unresectable or metastatic    ,GIST,Soft tissue,Sarcoma,NA,NA,0.27 (0.19-0.39),3,NA,NA,NA,0.9 month,3.9 months,3,NA,NA,NA,NA,NA,NA,PFS,NA,NA,NA,NA,21.07.2020,NA,21.07.2020,NA,NA,NA,NA,NA,NA,NA
Pazopanib,-,Placebo,Previously treated non-GIST metastatic soft tissue sarcoma,Sarcoma,Soft tissue,-,Metastatic,3,NA,NA,https://www.thelancet.com/article/S0140-6736(12)60651-5/fulltext,NA,NA,Placebo,NA,NA,NA,NA,Form 2b,PFS,Previously treated non-GIST metastatic soft tissue sarcoma,PALETTE,            Metastatic    ,NA,Soft tissue,Sarcoma,NA,NA,0.31 (0.24-0.40),3,NA,NA,NA,1.6 months,3.0 months,3,NA,NA,NA,NA,NA,NA,PFS,NA,NA,NA,NA,21.07.2020,NA,21.07.2020,NA,NA,NA,NA,NA,NA,NA
Eribulin,-,Dacarbazine,Unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease,Sarcoma,Soft tissue,Liposarcoma or leiomyosarcoma,Advanced or metastatic,3,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01283-0/fulltext,NA,NA,Dacarbazine,NA,NA,NA,NA,Form 2a,OS,Unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease,NA,            Advanced or metastatic    ,Liposarcoma or leiomyosarcoma,Soft tissue,Sarcoma,NA,NA,NA,3,11.5 months,2.0 months,0.77 (0.62-0.95),NA,NA,3,NA,NA,NA,NA,NA,NA,OS,NA,NA,NA,NA,21.07.2020,NA,21.07.2020,NA,NA,NA,NA,NA,NA,NA
Ridaforolimus,-,Placebo,Metastatic soft tissue or bone sarcomas after response or stable disease with 1st line treatment,Sarcoma,Soft tissue or bone,-,Metastatic,2,NA,NA,https://ascopubs.org/doi/full/10.1200/JCO.2012.45.5766?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed,NA,NA,Placebo,NA,NA,NA,NA,Form 2b,PFS,Metastatic soft tissue or bone sarcomas after response or stable disease with 1st line treatment,NA,            Metastatic    ,NA,Soft tissue or bone,Sarcoma,NA,NA,0.72 (0.61-0.85),2,NA,NA,NA,14.6 weeks,3.1 weeks,2,NA,NA,NA,NA,NA,NA,PFS,NA,NA,NA,NA,21.07.2020,NA,21.07.2020,NA,NA,NA,NA,NA,NA,NA
Imatinib 1-year,-,Placebo,Adjuvant for GIST patients had complete gross resection of a primary gastrointestinal stromal tumour at least 3 cm in size and positive for the KIT protein by immunohistochemistry,Sarcoma,Soft tissue,GIST KIT+,Adjuvant,A,NA,NA,https://www.thelancet.com/journals/lancet/article/PIIS0140673609605006/fulltext,NA,NA,Placebo,NA,NA,NA,A,Form 1,1-year RFS,Adjuvant for GIST patients had complete gross resection of a primary gastrointestinal stromal tumour at least 3 cm in size and positive for the KIT protein by immunohistochemistry,ACOSOG Z9001,            Adjuvant    ,GIST KIT+,Soft tissue,Sarcoma,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,RFS,NA,NA,NA,NA,21.07.2020,NA,21.07.2020,NA,NA,NA,83%,15%,0.35 (0.22-0.53),NA
Imatinib 3-years,-,Imatinib 1-year,Adjuvant for high-risk GIST patients with KIT-positive GIST removed at surgery,Sarcoma,Soft tissue,GIST KIT+,Adjuvant,A,NA,NA,https://jamanetwork.com/journals/jama/fullarticle/1105116,NA,NA,Imatinib 1-year,NA,NA,NA,A,Form 1,5-years RFS,Adjuvant for high-risk GIST patients with KIT-positive GIST removed at surgery,SSG XVIII,            Adjuvant    ,GIST KIT+,Soft tissue,Sarcoma,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,RFS,NA,NA,NA,NA,21.07.2020,NA,21.07.2020,NA,NA,NA,48%,18%,0.46 (0.32-0.65),NA
Nivolumab,Ipilimumab**,Placebo,Adult patients with resected stage IV melanoma with no-evidence of disease,Skin Cancers,Melanoma,-,Adjuvant,A,NA,NA,https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(20)30417-7.pdf,NA,NA,Placebo,NA,NA,NA,A,Form 1,RFS (Phase II),Adult patients with resected stage IV melanoma with no-evidence of disease,IMMUNED,            Adjuvant    ,NA,Melanoma,Skin Cancers,Ipilimumab**,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,RFS,NA,"*Calculated estimate of gain based on PE HR 0.23                                                                                                                                          **Licensed approval for adjuvant stage IV melanoma with no evidence of disease is with nivolumab as a monotherapy, ipilimumab combined with nivolumab was a planned arm of the same trial eligible for ESMO-MCBS scoring",NA,NA,22.07.2020,NA,22.07.2020,NA,NA,NA,6.4 months,21.4 months*,0.23 (0.12-0.45),NA
Nivolumab,-,Placebo,Adult patients with resected stage IV melanoma with no-evidence of disease,Skin Cancers,Melanoma,-,Adjuvant,A,NA,NA,https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(20)30417-7.pdf,NA,NA,Placebo,NA,NA,NA,A,Form 1,RFS (Phase II),Adult patients with resected stage IV melanoma with no-evidence of disease,IMMUNED,            Adjuvant    ,NA,Melanoma,Skin Cancers,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,RFS,NA,NA,NA,NA,22.07.2020,NA,22.07.2020,NA,NA,NA,6.4 months,6.0 months,0.56 (0.33-0.94),NA
Olaparib,-,Placebo,Monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen,Gastrointestinal Cancers,Pancreatic cancer,BRCA1/2 mutations,Metastatic,3,NA,NA,https://www.nejm.org/doi/full/10.1056/NEJMoa1903387?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed,NA,NA,Placebo,NA,NA,NA,NA,Form 2b,PFS,Monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen,POLO,            Metastatic    ,BRCA1/2 mutations,Pancreatic cancer,Gastrointestinal Cancers,NA,NA,0.53 (0.35-0.82),3,18.1 months,0.8 month,NS (immature),3.8 months,3.6 months,3,NA,No QoL benefit,NA,NA,NA,NA,PFS,NA,NA,NA,NA,23.07.2020,NA,23.07.2020,NA,NA,NA,NA,NA,NA,NA
Entrectinib,-,Single arm,Treatment of patients whose solid tumours have a neurotrophic tyrosine receptor kinase gene fusion,Refractory NTRK fusion–positive cancers,-,-,Locally advanced or metastatic,3,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30691-6/fulltext,NA,NA,Single arm,NA,NA,NA,NA,Form 3,"ORR,DOR",Treatment of patients whose solid tumours have a neurotrophic tyrosine receptor kinase gene fusion,NA,            Locally advanced or metastatic    ,NA,NA,Refractory NTRK fusion–positive cancers,NA,NA,NA,3,NA,NA,NA,11.2 months,NA,3,NA,NA,NA,NA,NA,NA,"ORR,DOR",NA,NA,NA,NA,NA,57%,23.07.2020,10.4 months,NA,NA,NA,NA,NA,NA
Entrectinib,-,Single arm,"Treatment of adult patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors",Thoracic Malignancies,Non-small-cell Lung Cancer,Refractory NTRK fusion–positive cancers,Advanced,3,NA,NA,https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30690-4/fulltext,NA,NA,Single arm,NA,NA,NA,NA,Form 3,"ORR, DOR","Treatment of adult patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors",NA,            Advanced    ,Refractory NTRK fusion–positive cancers,Non-small-cell Lung Cancer,Thoracic Malignancies,NA,NA,NA,3,NA,NA,NA,19.0 months,NA,3,NA,NA,NA,NA,NA,NA,"ORR, DOR",NA,NA,NA,NA,23.07.2020,77%,23.07.2020,24.6 months,NA,NA,NA,NA,NA,NA
Avapritinib,-,Single arm,Treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours harbouring the platelet-derived growth factor receptor alpha D842V mutation,Gastrointestinal Cancers,GIST,PDGFRA D842V-mutant,Unresectable or metastatic,3,NA,NA,https://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(20)30269-2.pdf,NA,NA,Single arm,NA,NA,NA,NA,Form 3,"ORR,DOR (Phase I)",Treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours harbouring the platelet-derived growth factor receptor alpha D842V mutation,NAVIGATOR,            Unresectable or metastatic    , PDGFRA D842V-mutant,GIST,Gastrointestinal Cancers,NA,NA,NA,3,NA,NA,NA,NA,NA,3,NA,NA,NA,NA,NA,NA,"ORR,DOR ",NA,Pending EU approval,NA,NA,06.08.2020,88%,06.08.2020,70% 12 months+,NA,NA,NA,NA,NA,NA
Durvalumab,Etoposide and either carboplatin or cisplatin,Platinum-etoposide,First-line treatment of extensive-stage small cell lung cancer,Thoracic Malignancies,Lung Cancer,Small-cell Lung Cancer,Extensive-stage,3,NA,NA,https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(19)32222-6.pdf,NA,NA,Platinum-etoposide,NA,NA,NA,NA,Form 2a,OS,First-line treatment of extensive-stage small cell lung cancer,CASPIAN,            Extensive-stage    ,Small-cell Lung Cancer,Lung Cancer,Thoracic Malignancies,Etoposide and either carboplatin or cisplatin,NA,NA,3,10.3 months,2.7 months,0.73 (0.59-0.91),NA,NA,3,NA,NA,NA,NA,NA,NA,OS,NA,Pending EU approval,NA,NA,06.08.2020,NA,06.08.2020,NA,NA,NA,NA,NA,NA,NA
